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1. Introduction
Recent developments in molecular biology and cell  biology have led to the discovery of
novel  genes  and  proteins  having  therapeutic  potentials  for  various  diseases  including
cancers.  Based on  these  findings,  novel  categories  of  therapeutic  biomacromolecules  in‐
cluding  genes,  small  interfering  RNA  (siRNAs),  antisense  oligonucleic  acids,  bioactive
proteins and peptides have been developed. These macromolecules can be more advanta‐
geous  than  small-molecular-weight  therapeutic  agents  in  terms  of  their  specificity  and
high  potency  to  the  target  molecules  [Nakase  et  al.,  2010].  Gene  therapy  is  the  newest
therapeutic  strategy  for  treating  human  diseases.  The  basic  idea  of  gene  therapy  is  a
gene or gene product that can be selectively delivered to a specific cell/tissue with mini‐
mal  toxicity.  This  product  can inhibit  the  expression of  a  specific  defective  gene  or  ex‐
press a normal gene.  Efficient and safe delivery is  one of  the key issues for the clinical
application of nucleic acids as therapeutic agents [Du et al.,  2010]. The goal of the Phar‐
maceutical Industry is to have a gene therapy medical product that can be delivered sys‐
temically.  In  vivo  gene  therapies  have  focused  on  viral  vectors  for  gene  delivery  and
have had marginal clinical successes. Major disadvantage of these delivery systems is the
integration  of  some viral  vectors  into  human chromosomes  of  normal  tissue.  There  are
four issues to be solved before cancer gene therapy will be successful: 1) Identification of
key target  genes critical  for  the disease pathology and progression;  2)  Determination of
the correct therapeutic gene to inhibit disease progression; 3) Optimal trans-gene expres‐
sion for suppressing the target gene; and 4) Delivery of therapeutic product to the target
tissue at an efficient dose [Scanlon, 2004].
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Delivery is one of the most difficult challenges facing the gene therapy field. It is needed
to use  an efficient  transfer  system that  can stabilize,  transduce and express  a  transgene
in the target tissue.  Recently,  non-viral  technologies have been widely used as a signifi‐
cant alternative for gene delivery.  The non-viral  delivery systems have reduced adverse
immune responses, are easier to manufacture and can be produced for the pharmaceuti‐
cal  industry  in  large  quantities.  The  current  progresses  of  gene  therapy  are  further  fo‐
cused  on  synthesized  nano-particle  technologies.  Some  of  these  new  chemical
compositions  are  cationic  molecules  such  as  polymers,  lipids  and  peptides  [Scanlon,
2004; Gao et al., 2007].
However, for successful clinical trial, ideal non-viral vectors should be degradable into low
molecular weight components, in response to biological stimuli, for lowered cytotoxicity and
effective systemic clearance. They should also be efficient in overcoming extracellular and
intracellular barriers, tissue/cell-targeted for specific accumulations and multi-functional for
synergistic therapeutic and diagnostic outcomes. Recently, a broad range of different stimuli-
responsive strategies (virus-mimicking gene delivery systems) has been employed to develop
non-viral nucleic acid carriers that efficiently enhance multiple extracellular and intracellular
gene delivery pathways by altering their physico-chemical properties in response to a variety
of extra- and intra-cellular stimuli (e.g., pH, redox potential, and enzyme), as well as external
triggers (e.g., light) [Zhu and Torchilin, 2012].
Therefore, numerous challenges remain to be overcome before gene therapy becomes available
as a safe and effective treatment option. For instance, the cationic molecules (e.g., polymers,
lipids and peptides) have the potential to be systemically delivered but selectivity for the target
tissue needs to be validated. The best method for delivering genes will depend on the type of
tissue targeted [Scanlon, 2004]. Recently, the development of virus-mimicking, multi-func‐
tional gene delivery systems is considered to be a potent strategy in the future, in particular
for intravenous administration. This chapter summarizes the challenges for cancer gene
therapy as well as addressing the advances in the multi-functional nano-carriers as a potent
non-viral delivery system.
2. Gene therapy
Medicine has a long history of treating patients with cell therapies (i.e., blood transfusions)
and protein therapies (i.e., growth factors and cytokines). Gene therapies are the newest
therapeutic strategy for treating human diseases especially cancer [Scanlon, 2004]. This
technology has been used to develop new strategies for killing cells selectively or inhibiting
their growth. The field of cancer gene therapy comprises a range of technologies from direct
attack on tumor cells to inducing the immune response to tumor antigens [McCormick, 2001].
However, there are serious doubts about gene therapy; for example, short-lived nature of gene
therapy, immune response to a foreign object, problems with viral vectors and insertional
mutagenesis inducing a tumor [Korthof, 1999].
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2.1. History
In 1972, Friedmann and Roblin published a paper in Science entitled as "Gene therapy for
human genetic disease" [Friedmann and Roblin, 1972; Rogers, 1970]. The first approved
gene  therapy  case  in  the  United  States  took  place  in  1990,  at  the  National  Institute  of
Health. It was performed on a four year old girl with a genetic defect associated to an im‐
mune system deficiency.  The  effects  were  only  temporary,  but  successful  [Blaese  et  al.,
1995]. In addition, sickle cell disease was successfully treated in mice [Fisher, 1995]. At the
same time, the researchers were able to create tiny liposomes 25 nanometers (nm) that can
carry therapeutic DNA through pores in the nuclear membrane [www. newscientist.com,
2002].  In  1992,  Claudio Bordignon performed the  first  procedure of  gene therapy using
hematopoietic stem cells as vectors to deliver genes aimed to correct hereditary diseases
[Abbott, 1992]. In 2002, this work led to the publication of the first successful gene thera‐
py treatment for adenosine deaminase-deficiency (SCID) [Cavazzana-Calvo et al., 2004]. In
2003, a Los Angeles research team inserted genes into the brain using liposomes coated in
a polymer called polyethylene glycol (PEG). The transfer of genes into the brain is a sig‐
nificant achievement because viral vectors are too big to get across the blood–brain barri‐
er.  This  method had potential  for  treating  Parkinson's  disease.  At  the  same time,  RNA
interference or gene silencing was considered as a new way to treat Huntington's disease
[www. newscientist.com, 2003]. In 2006, scientists at the National Institutes of Health have
successfully treated metastatic melanoma in two patients using killer T cells genetically re‐
targeted to attack the cancer cells.  For the first  time,  this  study demonstrated that  gene
therapy can be effective in treating cancer.  In November 2006,  Preston Nix reported on
VRX496, a gene-based immunotherapy for the treatment of human immunodeficiency vi‐
rus (HIV) that uses a lentiviral vector for delivery of an antisense gene against the HIV
envelope [Levine et al., 2006; www.eurekalert.org, 2009].
Leber's congenital amaurosis is an inherited blinding disease caused by mutations in the RPE65
gene. In 2007-2008, the world's first gene therapy trial was announced for inherited retinal
disease. They determined the safety of the sub-retinal delivery of recombinant adeno-
associated virus (AAV) carrying RPE65 gene and found the positive results in vision and
without the apparent side-effects [www. news.bbc.co.uk, 2007]. In 2009, the researchers were
succeeded at arresting a fatal brain disease, adrenoleukodystrophy, using a vector derived
from HIV to deliver the gene for the missing enzyme [Kaiser, 2009]. A paper published in 2010,
deals with gene therapy for a form of achromatopsia in dogs. Achromatopsia, or complete
color blindness, is presented as an ideal model to develop gene therapy directed to cone
photoreceptors [Komáromy et al., 2010]. In 2011, a study carried out using genetically modified
T cells to fight the chronic lymphocytic leukemia (CLL) disease. Moreover, Human HGF
plasmid DNA therapy of cardiomyocytes was examined as a potential treatment for coronary
artery disease as well as myocardial infarction [www. nature.com, 2011; Yang et al., 2008; Hahn
et al., 2011]. However, most of the approved European and United States gene therapy
protocols are for cancer (~ 66%), in contrast to monogenetic diseases (~ 11%) and cardiovascular
diseases (~ 8%). The focus of cancer gene therapy has been on melanoma, prostate and ovarian
cancer and leukemia [Scanlon, 2004].
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2.2. The challenges of gene therapy
Recently, the use of gene therapy in medicine using plasmid DNA (pDNA), oligodeoxynu‐
cleotide (ODN) or small interfering RNA (siRNA) represents a promising new approach for
treating a variety of genetic and acquired diseases (e.g., cancer). To date, more than 1000
different gene-therapy clinical trials for the treatment of many different diseases are in progress
worldwide, but, the success with gene therapy has been limited. This lack of success can be
assigned to difficulties related to the effective delivery of nucleic acids into target cells
[Mastrobattista et al., 2006]. Naked DNA is unable to efficiently cross cellular barriers by
passive diffusion because of its large size, strong negative charge, hydrophilicity and suscept‐
ibility to nuclease attack. Hence, the major challenge for in vitro DNA delivery is designing
suitable vectors which can protect DNA and efficiently deliver it to the targeted sites in the
cell. Successful application of such therapeutic vector-DNA formulations in vivo requires them
to be stable during circulation in blood, resistant against rapid metabolic clearance and
efficiently targeted to the appropriate tissue/cell [Mann et al., 2008].
3. Delivery systems in gene therapy
3.1. Viral delivery
Delivery is one of the most difficult challenges facing the gene therapy field. An efficient
transfer system has not yet been found to stabilize, transduce and express a transgene in the
target tissue. Limitations of the present vector technologies have slowed the progress of clinical
gene therapy [Scanlon, 2004]. Various viruses, such as influenza viruses and adenoviruses, can
efficiently deliver genes into the nucleus via sophisticated mechanisms. Despite the potent
immunogenicity of viral vectors, their developed cell entry mechanism and high transfection
efficiency in both dividing and non-dividing cells is desirable [Wagner, 2011; Mastrobattista
et al., 2006]. All the viral gene strategies used to date have significant delivery limitations. The
best method for delivering genes may depend on the type of targeted tissue. There are some
promising delivery technologies for viral therapies, including the use of replication competent
viruses. Adenoviruses, herpes simplex virus and Newcastle disease virus have all been modified for
replication competent properties in human tumor cells. This has been one of the most popular
areas in gene therapy and offers promises for treating cancer, especially when combined with
chemotherapy [Scanlon, 2004]. Recently, the viral vectors have been developed into gene
vectors and have provided convincing successes in gene therapy. Viruses have developed
mechanisms to survive in the extracellular environment, attach to cells, cross cellular mem‐
branes, steal intracellular transport systems and subsequently deliver their genomes into the
appropriate sub-cellular compartment (e.g., cytosol or nucleus) [Wagner, 2011; Sasaki et al.,
2008]. For example, influenza viruses infect cells in a multi-step process: a) the virus binds to a
receptor on the cell surface mediated by hemagglutinin (HA) protein; b) the virus invades via
receptor-mediated endocytosis; c) the internalized virus is trafficked to a late endosome; d) the
acidic endosomal environment induces membrane fusion between the virus and endosome,
which is brought about by a conformational change of HA and the ribonucleoprotein complex
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core is released into cytoplasmic space; e) the core is transferred to the nucleus and viral gene
expression progresses. Due to this very efficient cell-entry mechanism, the transfection
efficiencies of viral vectors remain uniqe [Sasaki et al., 2008].
However, there are several problems to overcome before this therapy can be successful in
clinical settings such as a) Enhanced lytic properties of these viruses; b) Improved yields with
better manufacturing procedures of production for clinical studies; c) Systemic delivery; d)
limited DNA-carrying capacity; e) lack of target-cell specificity; f) immunogenicity and h) for
some viral vectors, insertional mutagenesis [Scanlon, 2004; Mastrobattista et al., 2006].
3.2. Non-viral delivery
There are some non-viral technologies that offer several advantages over the viral meth‐
odologies. Non-viral delivery systems have reduced adverse immune responses (relative‐
ly  safe),  are  easier  to  manufacture,  can be  produced for  the  pharmaceutical  industry in
large quantities and modified by the incorporation of ligands for targeting to specific cell
types  [Scanlon,  2004;  Mastrobattista  et  al.,  2006].  Chemically  synthesized  nanoparticles
constitute a new technology and offer several new strategies for successful systemic gene
therapy delivery. Synthetic gene-delivery systems consist of a self-assembling complex of
DNA with positively charged molecules (for example, polymers, peptides, lipids or their
combinations).  These  complexes  are  small  in  size  (40-150  nm)  and  usually  have  a  net
positive surface charge,  which enables adsorption-mediated cell  binding and internaliza‐
tion [Mastrobattista et al.,  2006]. Some of these new chemical compositions are polymers
containing  either  DNA/stearyl  polylysine-coated  lipids  or  peptoids  (DNA  coated  with
glycine  oligomers)  or  cationic  molecules  (DNA/combined  with  positively  charged  B-cy‐
clodextrin/adamantane  and  PEG).  These  molecules  have  been  shown  to  be  effective  in
cancer-related angiogenesis.  These  new agents  have the  potential  to  be  systemically  de‐
livered,  but  their  selectivity  for  the  target  tissue  needs  to  be  validated  [Scanlon,  2004].
However,  the levels of gene expression and the transfection efficiency mediated by syn‐
thetic vectors are low compared to viral vectors [Mastrobattista et al., 2006].
3.3. Cell delivery
One of the opportunities for gene therapy is to combine therapeutic genes with a cell to
overcome the delivery to target tissues. The advantages of cell delivery of therapeutic products
include minimal immune response; tissue directed therapy; selectivity and improved potency
of the product. However, there are several problems to be solved: a) Determining optimal
transduction of cells; b) Gene-transformed cells will require a selective growth advantage over
defective cells to re-populate the host; c) DNA repair genes action (minimized mutations in
the gene-transformed cells); d) Genomic stability (for optimal gene expression); e) Determining
cell type for therapy (e.g., embryonic stem cells or activated, differentiated cells); f) Incorpo‐
ration of a safety mechanism (i.e. a suicide gene) to destroy the gene-transformed cells if a
problem arises. In addition, other cell therapies are currently being developed using bacteria,
such as modified Salmonella, for gene delivery in cancer patients. These modified bacterial cells
are already in Phase I clinical studies [Scanlon, 2004].
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4. The challenges of nucleic acid delivery
There are many biological barriers for efficient gene delivery that need to be overcome
[Mastrobattista et al., 2006]. This inefficiency of gene delivery is primarily a result of the
inability of these vectors to overcome the numerous barriers encountered between the site of
administration and localization in the cell nucleus. This series of barriers to efficient non-viral
gene delivery is thought to include: a) the physical and chemical stability of DNA and its
delivery vehicle in the extracellular space, b) cellular uptake by endocytosis, c) escape from
the endosomal compartments prior to trafficking to lysosomes, d) cytosolic transport and e)
nuclear localization of the plasmid for transcription. In addition to these physical and chemical
obstacles, biological barriers, such as immunogenic responses to the vector itself as well as
immune stimulation by certain DNA sequences containing a central un-methylated CpG motif,
are present. The studies have shown that it is possible to minimize biological barriers by
optimizing the plasmid sequence, thus physical and chemical barriers appear to be the negative
factors to successful non-viral gene delivery [Wiethoff and Middaugh, 2003]. These barriers
are briefly described as following:
4.1. Stability in extracellular compartments
The stability of non-viral delivery systems in the extracellular milieu, such as intercellular or
intravascular spaces, is related to the chemical stability of the DNA as well as the physical
stability of the delivery system [Wiethoff and Middaugh, 2003]. In extracellular environment,
the carrier is exposed to blood components such as nucleases. This can result in premature
destabilization with simultaneous release and degradation of the plasmid DNA. The half-life
of naked plasmid DNA in blood is on the order of minutes. Therefore, carrier-mediated
protection during transport through the blood circulation is a prerequisite to make the DNA
inaccessible to degradative enzymes [Mastrobattista et al., 2006]. Condensing the DNA with
a variety of polycations or by complexing with polymers that bind to DNA protects it from
degradation [Wiethoff and Middaugh, 2003].
4.2. Cellular association of DNA
Irrespective of the injection route, the gene carriers should be able to bind to cells for al‐
lowing cellular uptake [Mastrobattista et al., 2006]. Association of DNA with the cell sur‐
face  is  typically  very  low  in  the  absence  of  any  delivery  agent  as  an  immediate
consequence of the relatively high negative charge density of both the DNA and the cell
surface. Polycations have been shown to substantially increase the cellular association of
DNA by neutralization  of  the  DNA negative  charge,  with  the  charge  ratio  of  the  com‐
plex  modulating  the  extent  of  this  contact.  The  degree  of  cellular  association  has  also
been shown to be related to the colloidal  stability of  these delivery systems,  with those
that aggregate often manifesting a greater degree of cellular association in vitro.  The as‐
sociation of non-viral gene delivery systems containing either cationic lipids or polymers
is thought to be mediated by interactions with cell surface heparin sulfate proteoglycans
(HSPGs). These proteoglycans are ubiquitous to the surface of all  cells and are involved
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in a variety of cellular processes, including differentiation, adhesion and migration. More
recently they have been found to mediate the binding and internalization of  several  vi‐
ruses,  including HIV-1,  HSV-2,  AAV-2,  and adenovirus.  The composition of  heparin sul‐
fate  proteoglycans  (HSPGs)  includes  a  protein  core  with  one  or  more  attached
glycosaminoglycans [Wiethoff and Middaugh, 2003].
In general, binding of nano-carrier to the cell surfaces is not, a problem if the gene carriers have
a net positive surface charge, which readily induces adsorption onto negatively charged cell
membranes. However, this form of binding is random and does not allow restricted delivery
to target cells (e.g., tumor cells) [Mastrobattista et al., 2006]. Several additional strategies have
been attempted to increase the specificity of DNA binding to cells and induce targeting to
particular cell types [Wiethoff and Middaugh, 2003]. Active targeting can be achieved by the
functionalization of NPs with ligands such as antibodies, peptides, nucleic acids (aptamers),
carbohydrates and small molecules [Gu et al., 2007].
4.3. Intracellular trafficking of non-viral gene delivery systems
Since many chemotherapeutic drugs and particularly gene therapeutics, would benefit from
intracellular targeting, nano-carrier systems can be designed for receptor-mediated cell
uptake, intracellular drug protection and intracellular target delivery [van Vlerken et al.,
2007]. Once inside the cell, several intracellular barriers need to be crossed before the foreign
DNA can be transcribed and translated [Mastrobattista et al., 2006]. These barriers contain
endosomal escape, cytosolic transport of DNA and nuclear localization of plasmid DNA that
described briefly in below:
4.3.1. Endosomal escape
The endocytic pathway is one of the uptake mechanisms of cells. In general, non-viral nano
vectors have been developed to mimic the receptor-mediated cell entry mechanism of viruses
and the main mechanism of internalization was confirmed to be endocytosis. This pathway is
composed of vesicles known as endosomes with an internal pH around 5 that mature in a uni-
directional manner from early endosomes to late endosomes before fusing with intracellular
organelles called lysosomes which contain certain digestive enzymes. Thus, particles entering
the cells via the endocytic pathway become entrapped in endosomes and eventually end up
in the lysosome, where active enzymatic degradation processes take place [Varkouhi et al.,
2011]. The entrapment of internalized DNA carriers in endocytic compartments prevents
further intracellular transport towards the nucleus and will often result in degradation of the
carrier and its associated DNA in the endosomal/lysosomal compartments [Mastrobattista et
al., 2006]. While many viruses have evolved quite efficient systems for endosomal release, the
situation is different for non-viral vectors, where in many cases the lack of endosomal escape
is a major obstacle for efficient biological delivery, implying that more efficient methods for
endosomal release would lead to improvements in designing synthetic transfection systems.
In contrast to synthetic vectors, viral vectors are known to be efficient both for in vitro and in
vivo applications [Varkouhi et al., 2011].
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4.3.2. Cytosolic transport of DNA
After  endosomal  escape,  DNA  must  traverse  the  cytosol  to  access  the  nucleus.  Those
DNA carriers  that  manage  to  escape  the  endosomal  compartments  are  then  challenged
by  the  complex  environment  of  the  cytosol,  which  contains  many  filamentous  struc‐
tures  that  hinder  the  free  diffusion  of  large  particles  such  as  DNA  carriers.  Dissocia‐
tion  of  the  carrier  at  this  stage  might  be  required  to  allow  further  transport  of  the
plasmid  DNA  molecules.  However,  several  studies  have  found  evidence  that  plasmid
DNA is  largely  immobile  in  the  cytosol  and is  rapidly degraded by cytosolic  nucleases
[Mastrobattista  et  al.,  2006].  Diffusion  of  DNA  in  the  cytoplasm  has  been  found  to  be
substantially  less  than  that  observed  in  dilute  solution.  For  DNA  >2000  base  pairs  in
length,  the  diffusion  co-efficient  in  the  cytosol  is  <1%  of  that  in  water,  suggesting  a
substantial  diffusional  barrier.  This  decreased  mobility  has  been  ascribed  to  molecular
crowding  of  the  plasmid,  but  may  also  reflect  an  increased  viscosity  of  the  cytoplasm.
As  expected,  the  diffusion  coefficient  of  DNA  in  the  cytoplasm  is  inversely  related  to
the  size  of  the  plasmid,  suggesting  smaller  plasmids  may  be  more  desirable.  No  evi‐
dence  for  active  transport  of  DNA  in  the  cytoplasm  has  been  reported.  In  addition  to
the  considerable  diffusional  barrier  for  DNA  in  the  cytosol,  the  presence  of  calcium-
sensitive  cytosolic  nucleases  pose  a  significant  metabolic  barrier.  Micro-injection  of
DNA into  the  cytoplasm results  in  significant  degradation  of  the  DNA with  a  half-life
of  50-90 min [Wiethoff  and Middaugh,  2003].
4.3.3. Nuclear localization of plasmid DNA
Ultimately, delivery of DNA to the nucleus must occur for transcription of the transgene to
take place. The mechanism of DNA nuclear translocation and whether the DNA is still
associated with the delivery system are not fully understood but appear to depend on the type
of delivery vehicle employed. At least three possible routes exist for DNA transport to the
nucleus. The DNA can pass into the nucleus through nuclear pores, it can become physically
associated with chromatin during mitosis when the nuclear envelope breaks down or it could
traverse the nuclear envelope. Of these three possibilities, the latter seems impossible and
without experimental support. Nuclear pores are embedded in the nuclear envelope at fairly
high surface densities (3000-4000/nucleus) and exist in at least two conformational states. The
closed state permits the passive diffusion of molecules of < 9 nm in diameter, whereas the open
state facilitates transport of particles < 26 nm. This latter state could certainly assist the
‘‘threading’’ of supercoiled plasmid through the nuclear pore but not passage of typical non-
viral gene delivery complexes [Wiethoff and Middaugh, 2003]. Small molecules (< 40 kDa) can
diffuse freely through the pores of the nuclear pore complexes (NPC), whereas larger mole‐
cules and particles (up to 40 nm in size) can only be imported through the NPC by an active
transport mechanism [Mastrobattista et al., 2006]. In a few cases, collapsed particles of < 30 nm
have been produced, which could presumably enter the nucleus by this mechanism. The
second and perhaps quite widespread mechanism by which DNA is thought to gain access to
the nucleus is by association with nuclear material on breakdown of the nuclear envelope
during mitosis [Wiethoff and Middaugh, 2003]. In this case, the nuclear barrier breaks down,
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which explains the increased levels of transfection in dividing cells as compared to their
growth-arrested counterparts. However, as most cells do not divide or divide only slowly, an
active transport mechanism is needed to carry the DNA from the cytosol into the nucleus
[Mastrobattista et al., 2006].
4.4. Toxicity of non-viral delivery system
An important obstacle to effective non-viral gene delivery is the cytotoxicity of the delivery
vectors [Wiethoff and Middaugh, 2003]. Inside the nucleus, the transgene encoded on the
plasmid vector should be expressed to establish therapeutic levels of recombinant proteins
within the affected cell. This requires gene transcription regulatory elements such as promoters
and enhancers, to drive the expression of the transgene in mammalian cells. Viral promoters
are often used because of their strong transcriptional activation. However, their constitutive
nature does not allow control over the level of transgene expression. For the expression of
proteins with a narrow therapeutic window, tight control over the level of transgene expres‐
sion is essential. In addition, the introduction of foreign DNA into mammalian cells can induce
a profound immune response, presumably triggered by differences in the degree of methyla‐
tion of the foreign DNA compared with the mammalian genome [Mastrobattista et al., 2006].
Induction of innate immune responses by un-methylated CpG sequences in plasmid DNA is
perhaps a more serious concern because these species have been demonstrated to greatly
reduce the efficiency of non-viral gene delivery. This immunotoxicity is thought to be related
to the efficient transfection of immune cells because polycation/DNA complexes evoke a
considerably greater immune response than DNA or cationic vector alone. Initial observations
suggest that delivery systems that are phagocytosed, due to their large size, may promote a
greater immune response. Removal of CpG motifs from DNA containing the transgene has
proven a successful means of improving gene expression. The methods involved in producing
vectors without these motifs are not insignificant, and currently present a major limitation to
their widespread usage. It has therefore been proposed that avoidance of transfection of
immune cells either by specific targeting to particular cell types or by manipulation of the
physicochemical properties of the delivery systems is necessary for significant improvements
in non-viral gene delivery [Wiethoff and Middaugh, 2003].
5. Multi-functional nanocarriers
Currently used pharmaceutical nanocarriers, such as liposomes, micelles, nanoemulsions,
polymeric nano-particles and many others demonstrate a broad variety of useful properties
including: a) longevity in the blood allowing for their accumulation in pathological areas; b)
specific targeting to certain disease sites due to various targeting ligands attached to the surface
of the nanocarriers; c) enhanced intracellular penetration with the help of surface-attached cell-
penetrating molecules; d) contrast properties due to the carrier loading with various contrast
materials allowing for direct carrier visualization in vivo; e) stimuli-sensitivity allowing for
drug release from the carriers under certain physiological conditions and etc. Some of those
pharmaceutical carriers have already made their way into clinic, while others are still under
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preclinical development. However, the combination of pharmaceutical nanocarriers with
several mentioned abilities, are rare. For example, long-circulating immunoliposomes capable
of prolonged residence in the blood and specific target recognition represent one of few
examples of this kind. At the same time, the engineering of multi-functional pharmaceutical
nanocarriers combinig several useful properties in one particle can significantly enhance the
efficacy of many therapeutic and diagnostic protocols [Torchilin, 2006].
The use of cationic lipids and cationic polymers as transfection vectors for efficient intracellular
delivery of DNA was suggested in 1987. Complexes between cationic lipids (such as Lipofec‐
tin®, an equimolar mixture of N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium
chloride–DOTMA and dioleoyl phosphatidylethanolamine –DOPE) and DNA (lipoplexes)
and complexes between cationic polymers, such as PEI and DNA (polyplexes) are formed
because of strong electrostatic interactions between the positively charged carrier and nega‐
tively charged DNA. A slight net positive charge of formed lipoplexes and polyplexes is
believed to facilitate their interaction with negatively charged cells and improve transfection
efficiency. Endocytosis (including the receptor mediated endocytosis) was repeatedly con‐
firmed as the main mechanism of lipoplex/polyplex internalization by cells [Torchilin, 2006].
Of special importance is the fact that despite of endocytosis-mediated uptake lipolexes and
polyplexes, DNA does not end in lysosomes but releases in the cytoplasm due to the destabi‐
lization of the endosomal membrane provoked by lipid or polymeric component of the
complexes. In particular, lipoplexes fuse with the endosomal membrane when they contain a
fusogenic lipid, dioleylphosphatidylethanolamine (DOPE), which easily undergoes the
transition from bilayer to hexagonal phase facilitating the fusion. In case of polyplexes, which
cannot directly destabilize the endosomal membrane, the mechanism of DNA escape from
endosomes, is associated with the ability of polymers, strongly protonate under the acidic pH
inside endosome and create a charge gradient ultimately provoking a water influx and
endosomal swelling and disintegration. In both cases, DNA-containing complexes when
released into the cytosol, dissociate allowing for nuclear entry of free DNA. Nuclear translo‐
cation of the plasmid DNA is relatively inefficient because of the barrier function of the nuclear
membrane and small size of nuclear pores (25 nm), as well as DNA degrades fast under the
action of cytoplasmic nucleases. It was estimated that only 0.1% of plasmids undergo nuclear
translocation from the cytosol. The attachment of nuclear localization sequences to plasmid
DNA may significantly enhance its nuclear translocation and transfection efficiency. New
approaches in using multifunctional carriers for DNA delivery include the application of bi-
metallic nano-rods that can simultaneously bind compacted DNA plasmid and targeting
ligands in a spatially defined manner [Torchilin, 2006].
DNA–lipid amphiphiles self-assemble into novel “DNAsomes”-liposome-like core-shell
structures with subunits composed of branched DNA-lipid hybrid molecules. These DNA‐
somes can be precisely modified over a wide range in terms of both size and surface charge.
More importantly, DNAsome is a natural carrier of small interfering RNA (siRNA) due to
DNA-RNA base-pairing, enabling efficient co-delivery of drugs and siRNA. The DNAsome
represents a universal multi-functional drug vector for simultaneous delivery of drugs, tracer
dyes, or antibodies, along with genes, siRNA or antisense nucleic acids [Roh et al., 2011].
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6. Different types of nanocarrier systems
Over the last eight years, a laboratory at Northeastern University has developed an array of
multi-functional nanocarriers for the delivery of genes, drugs and imaging modalities. These
flexible platforms consist of polymeric and lipid systems that combine different modalities and
stimuli-responsive release properties [Jabr-Milane et al., 2008].
The diagnostic and/or therapeutic objectives of a multi-functional nanocarrier system deter‐
mine the design of the formulation. A review of the literature shows that there are many
different types of nanocarrier formulations for the diagnosis, imaging and treatment of a
wide spectrum of diseases. These multi-functional carriers share three main design compo‐
nents: platform (core) material, encapsulated payload/biologically active agents and target‐
ing/surface  properties.  Nanocarrier  platforms  can  be  categorized  as  organic-based,
inorganic-based or a hybrid combination. Organic nano-platforms include polymeric nano‐
carriers, lipid-based nanocarriers (e.g., liposomes and nanoemulsions), dendrimers and car‐
bon-based nanocarriers  (e.g.,  fullerenes and carbon nanotubes)  [Jabr-Milane et  al.,  2008].
Inorganic  nano-platforms include metallic  nanostructures,  silica  nanoparticles  and quan‐
tum dots. An example of a hybrid platform is colloidal gold encapsulated in liposomes or
superparamagnetic iron oxide particles encapsulated in polymeric nanoparticles. Selection
of the core material is highly dependent on the properties of the biologically active agents.
Inherent  and  dynamic  properties  of  the  agents  such  as  therapeutic  index,  lipophilicity,
charge and size should be considered. When combining therapeutic agents with each other,
with an imaging/diagnostic  modality,  or  with energy delivery,  the interaction of  system
components (i.e.,  synergy, quenching, enhanced toxicity) and release kinetics should also
be considered. Surface properties are the third design component of multi-functional nano‐
carriers. A common surface modification technique that decreases reticuloendothelial sys‐
tem (RES) clearance is the physical or covalent attachment of PEG chains to the nanocarrier
platform. Since tumor microvasculature is known to be highly fenestrated, colloidal parti‐
cles can accumulate by the enhanced permeability and retention (EPR) effect. PEG surface
modification increases circulatory residence time, which increases the probability of accu‐
mulation at the target. Block co-polymers of poly (ethylene oxide) (PEO) and poly (propy‐
lene oxide) (PPO) (e.g., Pluronics®) have also been used as surface conjugates to enhance
circulation and achieve passive targeted delivery [Jabr-Milane et al., 2008].
Recently, nanoparticulate systems have been also developed for therapeutic gene delivery.
Some researchers have developed glutathione-responsive nanoparticles for the delivery of
plasmid DNA. The nanocarrier platform consisted of thiolated gelatin which was synthe‐
sized using 2-iminothiolane to covalently modify type B gelatin (pI ~ 4.5). The release pro‐
files  of  cross-linked  and  non-cross-linked  thiolated  gelatin  nanoparticles  and  gelatin
nanoparticles  (control)  loaded with  fluorescein  isothiocyanate-conjugated dextran (FITC-
dextran)  were assessed in  the presence of  different  glutathione concentrations (from 0.1
mM to 5 mM). A higher percentage of FITC–dextran was released from non-crosslinked
nanoparticles compared to the cross-linked nanoparticles. The rate of FITC–dextran release
from  thiolated  gelatin  nanoparticles  enhanced  with  increasing  concentrations  of  gluta‐
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thione. Glutathione in the media enhanced the release of FITC-dextran from thiolated gela‐
tin  nanoparticles  by  about  40%,  while  only  a  20%  enhancement  was  seen  with  gelatin
nanoparticles [Jabr-Milane et al., 2008]. After establishing the rapid, stimuli-responsive re‐
lease profile of these particles, the thiolated gelatin nanoparticles were loaded with plas‐
mid DNA expressing green fluorescent protein (GFP). Upon incubation of the formulations
with murine fibroblast cells, fluorescence imaging revealed transfection and protein expres‐
sion after 6 h continuing as long as 96 h. Flow cytometry indicated that the cross-linked
thiolated gelatin nanoparticles had the highest transfection efficiency. These nanocarriers
are capable of rapid DNA delivery in response to intracellular glutathione. This nanocarri‐
er platform was further modified to develop an anti-angiogenic gene therapy for the treat‐
ment  of  cancer.  This  platform consisted of  PEG-modified thiolated gelatin nanoparticles
loaded with plasmid DNA encoding the soluble form of the extracellular domain of vascu‐
lar endothelial growth factor (VEGF) receptor-1 (sFlt-1). VEGF receptor over-expression in
cancer is associated with neo-vascularization; sFlt-1 was selected as it blocks the VEGF re‐
ceptor and the associated signal cascade [Jabr-Milane et al., 2008]. The PEG modified thio‐
lated  gelatin  nanoparticles  showed  superior  in  vitro  transfection  in  human  breast
adenocarcinoma cells when compared to plain gelatin nanoparticles, PEG-modified gelatin
nanoparticles,  thiolated  gelatin  nanoparticles,  Lipofectin–plasmid  DNA  complexes  and
naked plasmid. In vivo evaluation of the formulation in nu/nu mice bearing orthotopic hu‐
man breast adenocarcinoma (MDA-MB-435) xenografts established transfection and expres‐
sion  of  sFlt-1  as  assessed  by  ELISA,  western  blot  analysis,  tumor  volume,  microvessel
density and immunostaining. PEG-modified thiolated gelatin nanoparticles were effective
in transfection with sFlt-1 expressing plasmid DNA in vivo and showed significant suppres‐
sion of tumor growth in MDAMB-435 tumor-bearing mice. The expressed sFlt-1 was able to
suppress angiogenesis [Jabr-Milane et al.,  2008]. As such, PEG-modified thiolated gelatin
nanoparticles are a viable platform for the delivery of therapeutic DNA to tumor mass. In
addition, a system was developed for oral gene delivery. The nanoparticles-in-microsphere
oral system (NiMOS) consists of type B gelatin nanoparticles encapsulated in Poly-ε-capro‐
lactone (PCL) microspheres. Based on the successful transfection results with sFlt-1, type B
gelatin nanoparticles were selected to encapsulate and deliver DNA, while PCL was select‐
ed to protect the nanoparticles from degradation in the stomach and deliver the particles to
the intestine, where PCL is degraded by lipases. To evaluate the biodistribution of NiMOS,
the researchers encapsulated 111In-radiolabeled gelatin nanoparticles in PCL microspheres,
orally administered the formulation to fasted Winstar rats, harvested the tissues at differ‐
ent time points and compared the results to 111In-radiolabeled gelatin nanoparticles. The
gelatin  nanoparticles  showed  immediate  and  high  accumulation  in  the  large  intestine
whereas NiMOS accumulation was initially high in the stomach (after 1 h) [Jabr-Milane et
al., 2008]. It then transferred predominately to the large intestine after 2 h. To explore the
effect of this biodistribution profile on transfection, the formulations were loaded with re‐
porter plasmids expressing β-galactosidase (CMV-βgal)  or expressing GFP. DNA loaded
NiMOS were orally administered to fasted Winstar rats at an oral dose of 100 μg plasmid
DNA [Jabr-Milane et al., 2008].
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Five days after administration, the rats were sacrificed and the GI tract was harvested for
analysis. The results were compared to unloaded NiMOS formulations, naked plasmid and
loaded gelatin nanoparticles. Transgene expression was evident in the small and large
intestines with both reporter plasmids although GFP expression was more prominent with the
loaded NiMOS formulation relative to the controls. Similar results were obtained in studies
with Balb/c mice. Clearly, NiMOS is a promising system for targeted delivery of therapeutic
DNA to the GI tract [Jabr-Milane et al., 2008].
7. Design of multi-functional nanocarrier system
An artificial gene-delivery vector, with a multi-component architecture is able to overcoming
all the barriers, in which each component performs a different task in a planned fashion. The
design of multi-functional nano-carrier is a multidisciplinary task that requires a profound
understanding of the physico-chemical mechanisms that drive the assembly of such nano-
particles. One among many prerequisites for a successful carrier system for nucleic acids is
high stability in the extracellular environment. In addition, the biological processes that elicit
the cellular uptake and intracellular processing accompanied by an efficient release of the cargo
in the intracellular compartment of these gene delivery systems have to be well understood.
A promising strategy to create such an interactive delivery system is to exploit the various
biological stimuli. With greater understanding of physiological differences between normal
and disease tissues and advances in material design, there is an opportunity to develop nano-
carrier systems for target-specific drug and gene delivery that will respond to the local stimuli
[Qiao et al., 2010; Mastrobattista et al., 2006]. At present, many examples of versatile, self-
assembling nano-particles for the delivery of DNA can be found in literature and this number
is continuously growing. In this section, emphasis is placed on the functional components that
are needed for effective gene delivery and also the biological stimuli such as pH and redox
potential for the synthesis of multi-functional intelligent delivery systems. Briefly, Table 1
indicates these functional carriers.
7.1. Bio-compatible, bio-degradable nano-carriers
The artificial virus should preferably be constructed from materials that are biocompatible and
biodegradable to prevent carrier-induced toxicities and the accumulation of carrier compo‐
nents in the body. In general, lipids are well tolerated. Synthetic polymers, on the other hand,
have shown to induce some cytotoxicity in vitro and in vivo. It is difficult to predict, however,
which polymer will be cytotoxic and which not on the basis of the structure of the cationic
polymer. In general, low-molecular-mass cationic polymers are less toxic than high-molecular-
mass polymers. Peptides derived from L-amino acids are inherently biodegradable. However,
when proteins or peptides contain large numbers of positively charged or exposed hydro‐
phobic amino acids, they can destabilize biological membranes and thereby cause cytotoxicity
[Mastrobattista et al., 2006].
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Function Examples Reference
Bio-compatible, biodegradable
nanocarrier
Synthetic polymers:
Poly (D, L-lactide-coglycolide), Poly
(L-lactic acid),
Poly (epiloncaprolactone),
Poly (alkylcyanoacrylates)
Natural polymers:
Gelatin, Chitosan, Hyaluronic acid
van Vlerken et al., 2007; Mastrobattista
et al., 2006
Packaging nucleic acids into
compact nanoparticles
Polyethyleimine (PEI),
Polylysine (pLys)
Wagner, 2011; Walker et al., 2005
Long-circulation of nanocarrier Polysaccharides, Polyacrylamide,
Polyvinylalcohol,
PEG [PEGylated polyplexes]
van Vlerken et al., 2007; Mastrobattista
et al., 2006
Targeting molecules for the
development of targeted NPs
Monoclonal antibody, Affibody,
Aptamer, Oligopeptides, Growth
factor, Vitamin
Wang et al., 2011; Wagner, 2011;
Mastrobattista et al., 2006; Gu et al.,
2007; van Vlerken et al., 2007; Peer et
al., 2007; Alexis et al., 2008; Farokhzad
et al., 2006; Zhang et al., 2001;
Askoxylakis et al., 2005; Soudy et al.,
2011; Kim et al., 2006; Ogris et al.,
2003
Intracellular delivery Escape from the endosomal
compartment:
Influenza HA2 peptide,
melittin,
T-domain of the diphtheria toxin,
GALA peptide,
pH-sensitive polymers: PEI
Cytosolic un-packaging: Reduction-
sensitive polyplexes
Nuclear Import:
SV40 from the large tumor antigen
Simian virus 40,
M9 from nuclear ribonucleoprotein
Eliyahu et al., 2005; Shim and Kwon,
2012; Vercauteren et al., 2012; Du et
al., 2010; Schaffer et al., 2000;
Bauhuber et al., 2009
Table 1. The use of different formulations with specific functions for designing of multi-functional nanocarrier
systems
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Polymeric nano-particles offer significant advantages over other nano-carrier platforms
primarily since a remarkable flexibility in polymer matrices allows for tailoring of the nano-
particle properties to meet the specific planed need. Other advantages of polymeric nano-
particles include ease of production, ease of surface modification, encapsulation efficiency of
the payload, payload protection, large area-to-volume, slow or fast polymer degradation and
stimuli-responsive polymer erosion for temporal control over the release of drugs and
feasibility of scale-up and manufacturing. Some examples of the most commonly used
polymers for nano-carriers include the synthetic polymers such as poly (D, L-lactide-coglyco‐
lide) (PLGA), poly (L-lactic acid) (PLL), poly (epsiloncaprolactone) (PCL), poly (alkylcyanoa‐
crylates) and natural polymers such as gelatin, chitosan and hyaluronic acid [van Vlerken et
al., 2007; Mastrobattista et al., 2006].
7.2. Packaging nucleic acids into compact nano-particles
A prerequisite for every systemic nucleic-acid delivery system is stability in the blood stream
prior to reaching its target cell. Therefore, the carrier must prevent the premature release of its
load. Among the different delivery systems, nano-sized drug carriers are receiving consider‐
able attention. Through precise selection of candidate therapeutics and appropriate function‐
alization of the nano-carrier systems, it is possible to develop fairly sophisticated multi-
functional systems that can provide optimized anticancer therapy, a function that imparts
particular use in intracellular delivery and sub-cellular localization of drugs. Reversible nucleic
acid condensation by cationic proteins is a common natural process, e.g., in packaging of whole
mammalian genomes into chromatin, or RNA into organelles. Compaction is also a key
function of viral cores for protection against the degradative environment during infection.
Nucleic acids as macromolecules are subjected to a variety of environmental factors such as
pH or enzymes (e.g., nucleases) that can degrade or destroy them. Complexation of nucleic
acids by cationic polymers or lipids is a widely used method to reduce their sizes and prevent
their destruction by nucleases.
Reversibility is important; the delivered nucleic acid has to be accessible for subsequent tran‐
scription [Wagner, 2011]. Polyplexes are non-viral vectors consisting of DNA and polycations
have shown potential in systemic targeted gene delivery in various animal models, but suffer
from far lower gene transfer efficiency than viral vectors. To improve efficiency, researchers are
trying to engineer synthetic vectors with virus-like qualities. For successful condensation of
DNA into virus size particles, an excess of polycations is necessary, which results in a positive
surface charge. The positive surface charge on particles has been shown to be generally advanta‐
geous for cell uptake [Walker et al., 2005]. Polyionic interactions, hydrogen bonding and hydro‐
phobic interactions control the condensation of nucleic acids. In electrostatic complexes of
plasmid DNA (pDNA) with polycations such as polylysine (pLys) or polyethylenimine (PEI),
neutralization of approximately 10,000 negative phosphate charges of one pDNA molecule by
approximately 100 polycation molecules results in compaction into “polyplexes” with sizes of 20
to > 100 nm (depending on aggregation events). The polymer/ pDNA core may be regarded as the
engine of the delivery vehicle; for efficient and specific delivery, like in natural viruses, addition‐
al domains for cell entry and endosomal escape are required [Fig.1A & B; Wagner, 2011].
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Figure 1. A) Schematic model of the pH-sensitive polyplexes: Covalent attachment of active targeting ligands e.g.,
peptides, proteins, aptamers and small molecules to PEG; Formation of the polycation- pDNA polyplex through
charge-charge interaction; Complex shielded at physiological pH and deshielded at acidic pH. B) pH-reversible pEGy‐
lated lipopolyplexes: Formation of complex by mixing DNA and PEI (polyplex); Incubation of the cationic polyplexes
with liposomes (liposome-Pyridylhydrazone-PEG); Shielding in extracellular compartments and deshielding in acidic
medium (e.g., endosomes).
7.3. Long-circulation of nanocarrier
Both naked DNA and lipoplexes have showed rapid hepatic clearance during systemic
administration. The liver elimination of lipoplexes was due to phagocytosis by Kupffer cells.
Absence of any hydrophilic surface group on the particles, may lead to their interaction with
plasma proteins, opsonization and removal from the circulation. The mononuclear phagocytic
system (MPS) plays a key role in systemic removal of hydrophobic particles. In addition to
biodegradability and biocompatibility, the non-viral carrier should be ‘invisible’ to the innate
and acquired immune system of the patient in order to prevent unwanted immune reactions
against the carrier and, consequently, rapid clearance of carriers from the blood circulation
after intravenous administration. This can be achieved by adding a hydrophilic coat around
the carrier. The coat can consist of a lipid bilayer or hydrophilic polymers grafted onto the
surface of the carriers [Mastrobattista et al., 2006]. Among several strategies to impart particles
with stealth-shielding, including surface modification with polysaccharides, polyacrylamide,
and polyvinyl alcohol, surface modification with PEG and PEG co-polymers proved to be most
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effective, fueling its wide-spread use. PEG has a general structure of HO–(CH2CH2O)n–
CH2CH2–OH, including a polyether backbone that is chemically inert, with terminal hydroxyl
groups that can be activated for conjugation to different types of polymers and drugs. PEG
offers the advantage that it is non-toxic and non-immunogenic, leading to approval by the
United States Food and Drug Administration (FDA) for internal use in humans and inclusion
in the list of inactive ingredients for oral and parenteral applications [Fig. 1 A & B; van Vlerken
et al., 2007]. The protective (stealth) action of PEG is mainly due to the formation of a dense,
hydrophilic cloud of long flexible chains on the surface of the colloidal particle that reduces
the hydrophobic interactions with the RES. The chemically anchored PEG chains can undergo
spatial conformations, thus preventing the opsonization of particles by the macrophages of
the RES, which leads to preferential accumulation in the liver and spleen. PEG surface
modification, therefore, enhances the circulation time of molecules and colloidal particles in
the blood. The mechanism of steric hindrance by the PEG modified surface has been thor‐
oughly examined. The water molecules form a structured shell through hydrogen bonding to
the ether oxygen molecules of PEG. The tightly bound water forms a hydrated film around
the particle and prevents the protein interactions. In addition, PEG surface modification may
also increase the hydrodynamic size of the particle decreasing its clearance, a process that is
dependent on the molecular size as well as particle volume. Ultimately, this helps in greatly
increasing circulation half-life of the particles [van Vlerken et al., 2007]. In cancer therapy,
PEGylated polyplexes with elongated plasma circulation may take advantage of the “enhanced
permeability and retention” (EPR) effect. Long-term circulating nano-particles can extravasate
and passively accumulate at tumor sites due to the leakiness of tumor vessels and ineffective
lymphatic efflux (“passive tumor targeting”) [Wagner, 2011].
7.4. Targeting molecules for the development of targeted NPs
Appropriate packaging of nucleic acids and the use of PEG as a shield can help the complex
survive within the circulation without being degraded or taken up by the mononuclear
phagocyte system MPS. However, the next challenge for a PEGylated gene complex is to
specifically target to cells or tissue of interest. By taking advantage of increased expression
levels of receptors or antigens in diseased conditions, such as cancer, gene complexes can be
targeted using specific ligands, such as antibodies, peptides, proteins, small molecules and
RNA aptamer that recognize and bind to the cells of interest, resulting in high transfection
efficiency [Wang et al., 2011].
Viruses are optimized for surviving in the relevant body fluids. Their surface is decorated with
ligands for attachment to their target cell surface receptors. Often they use more than one
receptor type for intracellular uptake into host cells. In design of synthetic nano-particles, such
multivalent recognition and cell uptake mechanisms for nucleic acid delivery can be utilized
[Wagner, 2011]. A simultaneous effect of the surface modification of gene carriers are that the
positive surface charges are shielded, which significantly reduces the non-specific adsorption
onto cell membranes. This enables targeting of the gene carriers towards specific cell types by
conjugating ligands to the hydrophilic coat around the gene carrier that specifically bind
internalizing cell-surface receptors. In this way, delivery of the transgene and subsequent
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expression can be restricted to target cells. Several different types of targeting ligands have
been used for this purpose, including peptides, antibodies and vitamins. If targeting ligands
are directed towards internalizing receptors, receptor binding will lead to receptor-mediated
endocytosis of the targeted gene carriers, as they are small enough (< 200-300 nm). This route
of uptake is to be preferred as it ensures intracellular accumulation of gene carriers in a
receptor-specific way [Mastrobattista et al., 2006]. While it has been demonstrated that PEG
surface modification of nano-carriers causes a greater accumulation of drug at the tumor-site
by passive targeting, active targeting of the carrier can help in selection of the target cell-type
within the tumor site and internalization of the nano-particles to a greater extent inside the
target cells. Active targeting can be achieved by the functionalization of NPs with ligands such
as proteins (mainly antibodies and their fragments), nucleic acids (aptamers), or other receptor
ligands (peptides, carbohydrates and vitamins) [Gu et al., 2007]. Regardless of the targeting
moiety, the principle outcome is essentially the same, mainly improved tumor cell recognition,
improved tumor cell uptake, and reduced recognition at non-specific sites. PEG surface
modification provides an advantage whereby the terminal groups of PEG can be functional‐
ized to reactive groups for covalent coupling. Most commonly, PEG is functionalized to
reactive carboxylic acids, amine, or sulfhydryl groups, allowing for efficient covalent attach‐
ment of the wide variety of targeting ligands by amide bonding or disulfide bridge formation
[van Vlerken et al., 2007]. In this section, we describe some classes of targeting molecules.
7.4.1. Monoclonal antibodies
Monoclonal antibodies (mAb) are the first and are still the preferred class of targeting mole‐
cules. The mAb Rituximab was approved by the FDA for treating B-cell lymphoma in 1997.
Another successful therapeutic mAb is Trastuzumab (Herceptin), an anti-HER2 mAb which
binds to ErbB2 receptors and was approved by the FDA for treating breast cancer in 1998.
Cetuximab, which binds to epidermal growth factor receptors (EGFR), was approved for
treating colorectal cancer in 2004 and head/neck cancer in 2006. Bevacizumab, a tumor
angiogenesis inhibitor that binds to vascular endothelial growth factor (VEGF), was approved
for treating colorectal cancer in 2004. Trastuzumab and rituximab have been conjugated to
poly (lactic acid) (PLA) NPs resulting in conjugates that exhibit a six-fold increase in the rate
of particle uptake compared with similar particles lacking the mAb targeting. Today, over 200
delivery systems based on antibodies or their fragments are in preclinical and clinical trials.
Antibodies may be used in their native state or as fragments for targeting [Imai and Takaoka,
2006; Peer et al., 2007].
7.4.2. Affibodies as targeting ligands
In recent times, a novel class of small molecules called “affibodies,” which can be considered
antibody mimics, have been examined for targeting. Affibodies are a class of polypeptide
ligands that are potential candidates for tissue-specific targeting of drug-encapsulated
controlled release polymeric nanoparticles. Affibody molecules are relatively small proteins
(6-8 kDa) that offer the advantage of being extremely stable, highly soluble, and readily
expressed in bacterial systems or produced by peptide synthesis. The binding affinities of
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affibody molecules are considerably higher compared with the corresponding antibodies. The
binding pocket of an affibody is composed of 13 amino acids, which can be randomized to
bind a variety of targets. In contrast to monoclonal antibody, affibody has following advan‐
tages as a targeting ligand. First, the small size of affibody (MW: 6 kDa) guarantees its tissue/
cell penetration ability. Second, its functional end groups for chemical conjugation are
distanced from its binding site. Moreover, affibody has a robust structure, and can be easily
synthesized in a large-scale manner. All of these advantages make the affibody a valuable
ligand for targeted drug delivery [Alexis et al., 2008; Manjappa et al., 2011]. Recently, anti-
HER2 affibody was also employed as a targeting ligand for nano-scaled drug delivery systems.
Alexis et al. conjugated the anti-HER2 affibody to poly-(D, L-lactic acid)-poly (ethylene glycol)-
maleimide (PLA-PEG-Mal) copolymer for targeted delivery to cells that over-express the
HER-2 antigen [Alexis et al., 2008].
7.4.3. Aptamer targeting molecules
A novel class of molecules, referred to as nucleic acid ligands (aptamers), has been devel‐
oped to generate targeting agents. Aptamers are short single-stranded DNA or RNA oligo‐
nucleotides  or  modified  DNA  or  RNA  oligonucleotides  that  fold  by  intramolecular
interaction into unique conformations with ligand-binding characteristics. Like antibodies,
aptamers can be prepared to bind target antigens with high specificity and affinity. The use
of aptamers as targeting molecules has several potential advantages over antibodies. Ap‐
tamers with high affinity for a target can be prepared through in vitro selection; a process
called systemic evolution of ligands by exponential enrichment (SELEX) [Chai et al., 2011].
Conjugating aptamers to nanoparticles has shown to result in more efficient targeted thera‐
peutics  or  selective  diagnostics  than non-targeted NPs.  Farokhzad et  al  have developed
NP-aptamer  (NP-Apt)  conjugates  that  target  the  prostate  specific  membrane  antigen
(PSMA), a transmembrane protein that is up-regulated in a variety of cancers, using the
A10 aptamer [Farokhzad et al., 2004]. This formulation has been further evaluated in vivo in
a  tumor model  of  LNCaP prostate  cancer  cells,  which express  PSMA antigens,  and has
been shown to regress tumor size effectively following a single intra-tumor injection over a
109-day study [Farokhzad et al., 2006].
7.4.4. Oligopeptide-based targeting molecules
Recently, a number of tumor homing peptides have been reported that specifically target
cancer cells and show promising results for tumor targeted drug delivery. Peptides, being
smaller than other targeting ligands, have excellent tissue penetration properties and can be
easily conjugated to drugs and oligonucleotides by chemical synthesis. Peptides are nearly
invisible to the immune system and are not taken up in the reticuloendothelial system like
antibodies and so are expected to cause minimal or no side effects to bone marrow, liver, and
spleen [Gu et al., 2007]. For example, Cilengitide® is a cyclic arginine-glycine-aspartic acid
(RGD) peptide that binds to the cell adhesion integrin αvβ3 on endothelial cells results in
increased intracellular drug delivery in different murine tumor models and is currently in
phase II clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer.
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Despite the success mentioned, RGD-targeted therapy still encounters many challenges. First
challenge is the limitation associated with the non-specific adhesive nature of the RGD-integrin
targeting system. Integrins are extracellular receptors that are not only expressed on cancer
cells but also on nearly all epithelial cells and are therefore not cancer specific. Recent devel‐
opment of phage display screening methods has successfully isolated peptide ligands with
high specificity and affinity to cell-surface hormone receptors (LHRH receptors, somatostatin
receptors) and tumor vasculature antigens [Gu et al., 2007]. One of those is a dodecapeptide
identified through phage display by Zhang et al, referred to as peptide p160. Peptide p160
displays high affinity for the human breast cancer cell lines MDA-MB-435 and MCF-7 in
vitro with very little affinity for primary endothelial HUVEC cells [Zhang et al., 2001]. Fur‐
thermore, in vivo bio-distribution experiments in tumor-bearing mice, p160 showed a higher
uptake in tumors than in organs such as heart, liver, lung and kidney. Relative to the RGD-4C
peptide, p160 showed high accumulation in tumor versus normal organs [Askoxylakis et al.,
2005; Soudy et al., 2011; Zhang et al., 2001]. Despite the potential of peptide p160 as a potent
tumor homing peptide, its applicability would be largely hindered by its instability toward
proteases. To overcome this, peptides have to be chemically modified so that their blood
clearance is minimized in comparison with their rate of uptake at the target sites. The most
common strategies used to increase peptide proteolytic stability include introduction of D- or
un-natural amino acids and peptide cyclization. In a recent study, Soudy et al have developed
analogues of cancer targeting peptide p160 to improve proteolytic stability and maintain
specific affinity for breast cancer cells. These analogues are potentially safe with minimal
cellular toxicity and are efficient targeting moieties for specific drug delivery to breast cancer
cells [Soudy et al., 2011].
7.4.5. Growth factor or vitamin-based targeting molecules
Growth factor or vitamin interactions with cancer cells represent a commonly used targeting
strategy, as cancer cells over-express the receptors for nutrition to maintain their fast-growing
metabolism. Epidermal growth factor (EGF) has been shown to block and reduce tumor
expression of the EGF receptor, which is over-expressed in a variety of tumor cells such as
breast and tongue cancer [Peer et al., 2007].
One of the most extensively studied small molecule targeting moieties for drug delivery is folic
acid (folate). The high-affinity vitamin is a commonly used ligand for cancer targeting because
folate receptors (FRs) are frequently over-expressed in a range of tumor cells. It has been used
as a targeting moiety combined with a wide array of drug delivery vehicles including lipo‐
somes, protein toxins, polymeric NPs, linear polymers, and dendrimers to deliver drugs
selectively into cancer cells using FR-mediated endocytosis [Gu et al., 2007]. The folic acid-
PEGylated PEI polyplex was evaluated as a gene carrier, and successfully delivered siRNA
and pDNA to tumour cells [Kim et al., 2006].
Transferrin (Tf), an iron-binding glycoprotein interacts with Tf receptors (TfRs), which are
overexpressed on a variety of tumor cells (including pancreatic, colon, lung, and bladder
cancer) owing to increased metabolic rates. Direct coupling of these targeting agents to nano-
carriers has improved intracellular delivery and therapeutic outcome in animal models. Tf-
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linked PEG-PEI was developed for tumor-selective gene delivery. The surface charge of the
complexes was shielded by either PEG or a higher density of linked Tf to block undesired non-
specific interactions with blood components, followed by selective targeting to tumor cells.
This approach resulted in a 100-fold higher gene expression in tumor cells compared with
other tissues [Ogris et al., 2003].
One challenge with targeting receptors whose expression correlates with metabolic rate, such
as folate and Tf, is that these receptors are also expressed in fast growing healthy cells such as
fibroblasts, epithelial and endothelial cells. Therefore, NP delivery system needs to be further
refined and tuned to increase tumor selectivity [Gu et al., 2007; Peer et al., 2007].
7.5. Intracellular delivery
Non-viral vectors have to overcome multiple intracellular barriers subsequently after cellular
uptake usually via endocytosis. After cellular internalization, a critical intracellular obstacle to
non-viral gene delivery is degradation in the endosome/lysosome where nucleic acids are easi‐
ly degraded by a mildly acidic pH and acid activated enzymes. The ability of non-viral vectors
to release the nucleic acids in their intracellular targets, while surviving through low pH and di‐
gestive processes and avoiding unwanted premature decomplexation, is a key efficiency-deter‐
mining requirement. The most widely believed theory in designing non-viral vectors for
efficient endosomal escape is employing the “proton sponge effect” [Eliyahu et al., 2005]. Im‐
portantly, intracellular targets, where the nucleic acids are released from the vector, determine
the overall gene delivery efficiency because the action sites are different for nucleic acid types.
For example, plasmid DNA must be localized in the nucleus, where gene expression is initiated
by transcription. However, nuclear entry is one of the major obstacles to non-viral gene delivery
although nuclear translocation of plasmid DNA is crucial to achieve desired transfection effi‐
ciency. Moreover, the nuclear translocation mechanism of plasmid DNA in the cytoplasm has
not yet been fully elucidated. Passive diffusion of macromolecules (e.g., plasmid DNA) in the
cytoplasm is restricted by a complex network of microtubules, proteins, and various sub-cellu‐
lar organelles. One explanation is the nuclear localization of plasmid DNA during cellular mito‐
sis when the nuclear envelope disassembles. For non-dividing cells, the transport of polyplexes
into the nucleus occurs only via an active transport mechanism through a nuclear pore complex
that prevents molecules larger than 40 kDa from passively diffusing into the nucleus. In con‐
trast to plasmid DNA delivery, it is obvious that transnuclear localization of siRNA should be
prevented to achieve efficient RNA interference (RNAi) since siRNA acts in the cytosol, where it
targets mRNA with matching sequences [Shim and Kwon, 2012]. As nano-medicines often re‐
quire delivery of their therapeutic payload to specific sub-cellular locations, knowledge about
intracellular trafficking might prove useful for the control of the intracellular processing of
nano-particles and lead to optimization of their design [Vercauteren et al., 2012].
7.5.1. Escape from the endosomal compartment
Following internalization of peptide-DNA condensates by endocytosis, the polyplex must be
able to escape the endosome so that the DNA can be delivered to the nucleus for gene expres‐
sion. After endocytosis, entrapment of the vector within the acidified vesicles of the endosomal/
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lysosomal system is a critical barrier to non-viral gene delivery systems. Unfortunately, the en‐
vironment of the lysosomal interior is harmful for nucleic acid (NA) integrity, unless the carrier
offers sufficient protection against the degradation by the acid hydrolases [Vercauteren et al.,
2012]. Viruses and some pathogenic bacteria have pH-sensitive surface proteins that change
conformation in mildly acidic environments such as in endosomes, and exhibit membrane-dis‐
ruptive (fusogenic or endosomolytic) properties. Synthetic fusogenic peptides that mimic the
sequences of these natural proteins have been confirmed to increase cytoplasmic gene delivery
[Du et al., 2010]. Since escape from the endosomes is essential for efficient NA therapy, much at‐
tention has been paid to this issue, resulting in a variety of endosomolytic carriers. For example,
cationic and pH-responsive lipids can be added to phospholipid carriers to assist in releasing
the NAs into the cytoplasm by destabilizing the endosomal lipid bilayer in the acidic environ‐
ment of the endolysosomes. Another approach is based on the coupling of fusogenic peptides to
the carriers, which undergo conformational changes after their exposure to the decreasing en‐
dosomal pH values, exposing hydrophobic faces of the fusion peptide which destabilizes the
endosomal membrane. Examples of these endosome-disruptive peptides are the influenza
HA2 peptide, melittin, the T-domain of the diphtheria toxin or the GALA peptide [Vercauteren
et al., 2012]. In an effort to translate the proton sponge activity to gene delivery peptides, histi‐
dine has been added to peptide sequences. The imidazole group of histidine has a pKa of ~ 6.0,
therefore allowing it to become protonated in the acidic environment of the endosome. At phys‐
iological pH the histidines will remain neutrally charged, thereby imparting selective mem‐
brane disruption in the acidic endosome. In the past two decades, synthetic pH-sensitive
polymers as endosomolytic agents have attracted great interest due to their low or non immu‐
nogenicity, which is a concern of using fusogenic proteins or peptides. Polymers such as PEI
contain several secondary amines that are easily protonated in the acidic environment of the en‐
dosome. As protons are pumped in, PEI absorbs the protons leading to endosomal swelling and
membrane disruption. In general, these smart polymers have both hydrophobic parts and
weakly acidic groups, which afford them pH-dependent endosomolytic properties. At physio‐
logical pH, the polymers have little endosomolytic activity but undergo a conformational
change at endosomal pH and show membrane-disruptive properties. This provides the poly‐
mers with reduced toxicity to the other biomembranes at neutral pH, but with the ability to facil‐
itate endosomal escape [Fig. 1A; Du et al., 2010].
7.5.2. Cytosolic un-packaging
The final step of the gene delivery process, un-packaging of the polyplex, can limit the
efficiency of gene delivery and expression. For in vivo polyplex gene delivery, the polycation
condenses the DNA to protect it and facilitate its entry and passage through target cells.
However, once inside the nucleus, in order to be processed by RNA transcription complexes,
the DNA may first need to dissociate from the polycation. Strong binding of the polycations
to the nucleic acids may limit the intracellular un-packing of the polyplexes which is necessary
for an efficient transfection. Although some viruses have evolved highly specific and intensive
mechanisms for uncoating within the cell, a synthetic polycation may not release DNA with
similar high efficiency [Schaffer et al., 2000]. One of the solutions to these problems is to use
degradable polycations. Although the degradable polycations whose degradation is based on
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the hydrolysis of an ester or amide bond have been widely used as gene carriers with decreased
cytotoxicities, it is difficult to control the degradation occurring in the cytoplasm where free
siRNA should be released to take action. Since the reduction potential in the cytoplasm is much
higher (100 fold) than in the extracellular environments, a promising strategy to create an
interactive delivery system is to exploit the redox gradient between the extra- and intra-cellular
compartments, reduction-sensitive polyplexes are considered to be superior degradable
candidates, especially for siRNA delivery [Bauhuber et al., 2009; Du et al., 2010].
7.5.3. Nuclear import
The nuclear envelope that separates the cell’s genetic material from the surrounding cytoplasm
represents a physical barrier for nuclear import of macromolecules such as pDNA. The nuclear
envelope contains openings in the form of nuclear pore complexes, which allow free diffusion
of molecules up to 50 kDa, corresponding to a hydrodynamic diameter of approximately 10
nm. There are several lines of evidence showing that nuclear import is a rate-limiting step for
transfection of pDNA. Nuclear import of pDNA may be more challenging for transfection of
non-dividing cells. Indeed, non-dividing cells showed a 90% lower expression level as
compared to actively dividing cells. Strategies for nuclear import of genes have been developed
following further elucidation of the endogenous nuclear import machinery [Wang et al., 2011].
In nature, large molecules with sizes up to 30 nm in diameter that require trans-nuclear
transport contain nuclear localization signals (NLS) that are recognized by nuclear transport
receptors like importins or transportins, and the whole complex is thereafter actively trans‐
ported through NPCs [Vercauteren et al., 2012]. The nuclear localization sequence is a major
player that shuttles protein–plasmid complexes through the nuclear pore. NLS-mediated
active nuclear translocation involves a process starting from its interaction with cytoplasmic
importins to binding of the NLS to the nuclear pore complex and the passage through the pore.
Identification of the NLSs, such as SV40 from the larger tumor antigen Simian virus 40 and M9
from nuclear ribonucleoprotein, enabled design of non-viral gene vectors with nuclear
targeting properties [Wang et al., 2011].
8. Designing switchable nanosystems for medical application
To enhance therapeutic efficacy while minimizing side effects, a large number of nanomate‐
rial based platforms have been developed that allow simple delivery of genes. Based on im‐
portant earlier work in the field of liposomal gene delivery and inorganic nanomaterials,
the last  decade has brought a broad array of  new and improved nanoscale carrier plat‐
forms  such  as  biodegradable  and  non-degradable  polymers,  dendrimers,  carbon  nano‐
tubes,  metallic  and  organic  nanoparticles,  quantum  dots,  nanogels  or  peptidic
nanoparticles. Ideally, gene vectors should be capable of self-assembly with nucleic acids
and accommodate with any type of nucleic acid or their combination. They should also tar‐
get cells of interest, escape from endosomes and/or transport into nuclei. A viable gene vec‐
tor  for  systemic  delivery  needs  to  minimize  toxicity  and  phagocytosis  and  avoid  non-
specific  interactions  and self-aggregation.  For  potential  gene  delivery  applications,  ideal
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gene carriers need to combine both the targeting property and the stimulus responsiveness
to enhance the bioavailability of the gene as well as to reduce the side effects. Therefore,
designing stimulus-responsive nanoparticles for programmed gene delivery, which release
the gene on arrival at the targeted site, is highly desired. Stimulus-responsive nanoparticles
produce physical or chemical changes when subjected to external signals, including varia‐
tions of macromolecular structures, solubility, surface properties, swelling and dissociation
[Lehner et al., 2012]. Stimulus-responsive nanoparticles can be classified based on the type
of stimulus as internally and externally controllable materials. Internal stimuli (e.g. activa‐
tion by pH, redox potential, enzymes) might be controlled by a molecular mechanism high‐
ly specific for a disease and therefore improve on targeting properties. However, absolutely
disease-specific internal molecular triggers are difficult to find for certain diseases. External
stimuli like light, ultrasound, electromagnetic fields or ionizing radiation have the advant‐
age of being focusable on certain body areas. This may be a significant advantage where a
target cell is strongly involved in pathogenesis at one location (e.g., cancer stem cells in a
cancer tissue), but of vital importance in other locations (e.g., stem cells in the bone mar‐
row).  A  key  challenge  in  externally  controlled  nanomaterials  is  tissue  penetration  and
avoidance of undesired tissue damage in the radiation path from radiation source to target
tissue. The ease of temporal control in external stimuli may represent a particular advant‐
age for certain applications [Lehner et al., 2012]. Herein, we focus on the use of internal and
biological stimuli that can be used to incorporate switch functionality into such nanocarri‐
ers and describe the clinical experience with various nanosize carrier systems as a basis for
the design of new, improved, functional and “intelligent” nanosystems for gene delivery.
8.1. pH differences for stimuli-responsive delivery
The main property that is the basis of utilization of pH responsive polymers in gene delivery
is the significant change in pH value within the cellular compartments. There are numerous
pH gradients in physiological and pathological processes [Du et al., 2010]. The pH profile of
pathological tissues, such as inflammation, infection and cancer, is significantly different from
that of the normal tissue. The pH at systemic sites of infections, primary tumors, and meta‐
stasized tumors is lower than the pH of normal tissue. The pH, surface charge and density of
low density lipoprotein receptors are the factors that show notable differences among the
normal and tumor tissues. All these properties are known to influence the drugs’ physico‐
chemical properties and are exploited for enhanced delivery to the target site. The extracellular
pH values of solid tumor are in general slightly lower than in blood or other normal tissues.
Since tumors proliferate very rapidly, the vasculature of tumor is often insufficient to supply
enough nutritional and oxygen needs for the expanding population of tumor cells. This results
in difference in metabolic environment between the various solid tumors and the surrounding
normal tissue. The insufficient oxygen in tumor leads to hypoxia and causes production of
lactic acid and hydrolysis of ATP in an energy-deficient environment contributes to an acidic
microenvironment, which has been found in many tumors. Most of the solid tumors have
lower extracellular pH (6.5) than the surrounding tissues (pH= 7.5). The pH is compartmen‐
talized in tumor tissue into an intracellular component (pHi), which is similar in tumor and
normal tissues and an extracellular component (pHe), which is relatively acidic in tumors
Novel Gene Therapy Approaches220
[Ganta et al., 2008]. This behavior can be utilized for the preparation of stimuli responsive drug
or gene-delivery systems, which can exploit the biochemical properties at the contaminated
site for targeted delivery. Cellular components such as the cytoplasm, endosomes, lysosomes,
endoplasmic reticulum, golgi bodies, mitochondria and nuclei are known to maintain their
own characteristic pH values. It is well known that the lower pH values are found in endo‐
somes (5.5-6.0) and lysosomes (4.5-5.5). On the basis of these discoveries, various pH/acid-
sensitive polymers have been developed as carriers for pDNA, ODN or siRNA delivery [Du
et al., 2010; Ganta et al., 2008].
8.1.1. Low pH-sensitive reversible shielding/masking
This part focuses on the design and synthesis of polymeric carriers that can condense a
large dose of therapeutic nucleic acids into particles that can sense the differences in envi‐
ronmental pH. The pH-modulated or self-regulated polymers are designed to use these pH
differences  by  incorporating  appropriate  structural  or  functional  features  into  the  basic
scaffold of the polymers to improve the efficacy of gene delivery. In general, polycations
(PCs), such as PEI or dendrimers (polyplexes) or with cationic lipids (lipoplexes) with posi‐
tively charged surfaces are preferred for gene delivery in cell culture [Du et al., 2010]. Al‐
though, these positively charged particles are favorable for gene transfer efficiency in vitro,
they are problematic for systemic gene targeting. Upon systemic application of positively
charged cationic lipid based formulations (CL), polycations and lipopolyplexes may result
in  significant  toxicity  and/or  poor  efficiency  due  to  plasma protein  binding,  interaction
with blood cells or activation of the complement system and therefore has limited their ap‐
plication for in vivo uses via systemic administration [Du et al., 2010; Walker et al., 2005]. In
general, the toxicity of cationic polymers increases with molecular weight, branched poly‐
mer morphology, and cationic charge density. A common approach for masking the sur‐
face  charge  of  polyplexes  is  to  coat  particles  with  a  hydrophilic  polymer  such  as
polyethylene glycol (PEG). Shielding the cationic surface by PEGylation and tailoring cati‐
onic density and polymer morphology have been popularly exploited to reduce the cyto‐
toxicity  [Shim  and  Kwon,  2012].  PEGylation  of  polyplexes  prevents  their  aggregation,
lowers toxicity,  increases circulation time and improves systemic targeted gene transfer.
Unfortunately, at the same time as shielding improves the properties of polyplexes for sys‐
temic application it appears to reduce its cell transfection activity due to two important bar‐
riers such as reduced cellular uptake and inadequate release of the transported gene at the
target cells.  The cellular uptake has been enhanced by attaching targeting ligands to the
polyplexes, however, the transfection efficiency of the targeted PEG vectors often still does
not reach the level of the uncoated gene vectors. This suggests that the stable shield may al‐
so hinder intracellular gene transfer steps following endosomal uptake. Therefore, it is clear
that to develop an optimal nonviral system for systemic application it must have a more
dynamic character [Du et al., 2010] Its surface charge must be neutralized during circula‐
tion but after reaching its target cell, the cationic surface charge should be re-exposed for
efficient  gene  transfer.  In  order  to  solve  these  conflicting issues,  pH-sensitive  reversible
shielding or masking strategies have been developed through pH-sensitive PEGylation of
lipid- or polymer-based carriers as the PEG shield intended to be removable in intracellular
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endosomes or in the slightly acidic extracellular microenvironment of tumors. Lipoplexes
and polyplexes containing a pH cleavable PEG shield were found to be less effective in
gene transfer than the corresponding stably shielded particles. There is a strategy to over‐
come this challenge. The neutralizing shield is attached to the DNA polyplex core via an
acid-labile linkage forming a shielded particle for systemic circulation. Chemical linkages
that may display pH-dependent hydrolytic degradation, once internalized into endosomal
and lysosomal compartments include acetal-ketal linkage, vinyl ether, orthoesters, and hy‐
drazones. Under the acidic environment of the endosomal compartment, these linkages un‐
dergo  acid-induced  hydrolysis  and  thereby  trigger  deshielding  of  the  polyplex  core.
Therefore, the acid-labile bioreversible shielding polymer exerts a significant impact on the
outcome of transfection efficiency [Du et al., 2010].
Walker and colleagues reported reversible shielding of polyplexes with pH-triggered de‐
shielding properties, enabled by conjugating PEG to the polycations poly-L-lysine (PLL) and
PEI via a pH-sensitive hydrazone bond (PC-HZN-PEG) of acyl hydrazides or 2-pyridyl
hydrazines. The reversibility of the hydrazone bond within conjugates was determined at
physiological and endosomal acidic pH, identifying suitable linker systems for endosomal
deshielding. The polyplexes with the acid-sensitive linkages showed much higher plasmid
gene delivery efficiencies (1-2 orders of magnitude) than those with stable linkages, both in
vitro and in vivo [Walker et al., 2005].
Sawant et al. demonstrated that the use of a lowered pH-degradable PEG-Hz-PE produced
particles (polyethylene glycol-phosphatidylethanolamine conjugates) with transfection
activity sensitive to changes in pH, which has a promise for site-specific transfection of tumor
cells in vivo. In this study, the encapsulation of PEI-PE/DNA complexes into pH-sensitive
micelle-like PEG-Hz-PE coat increased the stability of DNA in complete medium and increased
transfection efficiency by being responsive to changes in pH. In vivo, the PEG2000-Hz-PE is
expected to shield the PEI-PE/DNA complex in the systemic circulation and expose the
complex only at the tumor sites where the pH is slightly acidic and can facilitate the removal
of the PEG coat [Sawant et al., 2012].
Murthy et al. synthesized ‘encrypted’ polymeric carrier that consisted of hydrophobic,
membrane disruptive methacrylate polymers onto which hydrophilic PEG chains have been
grafted through acid-degradable acetal linkages; a p-aminobenzaldehyde acetal linkage
demonstrated a suitable hydrolysis profile at endosomal pH [Murthy et al., 2003].
In 2007, Knorr et al. synthesized a new PEGylation reagent containing p-piperazinobenzalde‐
hyde acetal linkage and a maleimide moiety which can be coupled to thiol-functionalized
compounds. For reversible shielding of polyplexes, PEG-acetal-maleimide (MAL) was
conjugated to PEI. At 37оC, the PEG-acetal-PEI conjugate were found to be shielded and stable.
In contrast, at endosomal pH, the particles were deshielded and aggregated within 0.5 h. The
reversibly shielded (PEG-acetal-PEI) polyplexes were found to have approximately 10-fold
enhanced gene transfer efficiency than stable shielded polyplexes when tested on the two
different cell lines, Renca-EGFR cells and K562 cells [Knorr et al., 2007].
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Recently, Sethuraman et al. have developed pH-Responsive Sulfonamide/PEI nanoparticles
that effectively target the acidic extracellular matrix of tumors, which shows a sharp pH profile,
was able to shield positively charged complexes at physiological pH of 7.4. The pH sensitive
polymer was able to detach from the complex when the pH environment decreased to pH=
6.6. The polymeric nanoparticle formed through electrostatic attraction is designed in such a
way that the final particle is neutral. The polyplexes formed by PEI and pDNA were coated
electrostatically with an ultra pH-sensitive diblock copolymer, poly (methacryloyl sulfadime‐
thoxine)-b-PEG. The central idea of this design is that when the particles experience a decrease
in pH as they extravasate into tumor tissue due to enhanced permeability and retention effect,
the sulfonamide groups would lose their charge and get detached from the carrier complex.
Most of the carriers developed so far do not have the high sensitivity that is required to respond
to such small differences in pH between tumors and normal tissues. This is because the
carboxylic acid based polymers show transitions in about one pH unit which is very broad,
and that transition is much below the physiological and tumor pH range, whereas the
poly(methacryloyl sulfadimethoxine) (PSD)-block-PEG PSDb-PEG polymer shows transition
within 0.2 pH units between the physiological and tumor pH. These sulfonamide polymers
are able to distinguish the small difference in pH between normal and tumor tissues and hence
has remarkable potential in drug targeting to tumor areas [Sethuraman et al., 2008].
8.1.2. pH-dependent endosomolytic polymers
Following internalization of lipoplexes or polyplexes via the endocytic pathway, endosomal
entrapment and subsequent lysosomal degradation are a major blockage that limits the
efficiency of gene delivery. After cellular uptake of the gene carriers, the carrier should escape
from the endosomal compartment in order to reach the cytosol and then, the nucleus. This
requires dissociation of the internalized carrier from the receptors that triggered the internal‐
ization process. In addition, the membranes of the endosomes should be destabilized to allow
translocation of the carriers into the cytosol [Mastrobattista et al., 2006]. Identification of
endosomolytic or fusogenic components and their integration into non-viral gene delivery
systems are major strategies being exploited to facilitate endosomal escape.
In the case of polyplexes, PEI and polyamidoamine (PAMAM) are two representative cationic
polymers with a high efficiency of gene transfer due in part to their capability to facilitate
endosomal escape. A “proton sponge effect” provides a sound explanation for the intrinsic
endosomolytic activity. Upon PEI-based or PAMAM-based polyplex entry into acidic endo‐
somes, the polymer behaves as a sponge that absorbs protons as a result of protonation of the
polymer-containing amine groups (primary, secondary and tertiary). Accumulation of protons
subsequently drives an influx of counter chloride ion into endosomes, leading to increased
osmotic pressure and subsequent flow of water into the endosomal interior and eventually
swells and ruptures endosomal membrane [Eliyahu et al., 2005].
PEIs are available in a wide range of molecular weights (MW) from 423 Da to 800 kDa and
with different branching degree (from linear to branched). Generally, high MW, branched PEIs
have high transfection efficiency but also high toxicity due to high cationic charge. By contrast,
low MW PEIs are less toxic but less efficient as gene delivery agents. Many efforts have been
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directed towards creating PEI derivatives combining higher transfection efficacy and good
biocompatibility. One approach to reduce the cytotoxicity, biodegradable polyethylenimine
with imine linkages as acid-labile moieties were synthesized and investigated for pDNA
delivery. The half-life of the acid-labile PEI was 1.1 h at pH= 4.5 and 118 h at pH= 7.4, suggesting
that the acid-labile PEI may be rapidly degraded into non-toxic low molecular weight PEI in
acidic endosome. Acid-labile PEIs showed close transfection efficiency to PEI 25KDa, but much
less toxicity due to the degradation of acid-labile linkage. Therefore, the acid-labile PEIs may
be useful for the development of a non-toxic polymeric gene carrier [Kim et al., 2005].
The cationic lipids have been shown to destabilize the endosomal membrane. Addition of
dioleoyl phosphatidylethanolamine (DOPE) or cholesteryl hemisuccinate (CHEMS) to non-
viral vectors affected the pH-sensitivity of the formulations. The mechanism behind the
phenomenon, is that electrical interaction between cationic lipids and anion endosomal
membranes results in the formation of ion-pairs that promote the formation of the inverted
hexagonal (HII) phase and disrupt endosomal membrane. Many preparations of lipoplexes
contain DOPE as a helper lipid for fusogenic functionality. The ability of DOPE to destabilize
endosomal membranes is based on its propensity to acquire an inverted hexagonal phase (HII).
DOPE has a small cross-section head group and a large hydrocarbon area that favors a non-
bilayer structure with a cone shape that facilitates the destabilization of endosomal membranes
and gene transfection. The pH-responsive component, CHEMS, being negatively charged at
neutral pH stabilizes the bilayer structure, however, at acidic pH it becomes protonated and
loses its stabilization property [Ma et al., 2007; Wu and Zhao, 2007].
Another approach to reduce the cytotoxicity of PEI is modification with hydrophobic moi‐
eties, such as lipids. Since lipids are the main component of cell membrane, modification
with hydrophobic moieties may result in additional hydrophobic interaction between poly‐
plexes and cell membranes, which in turn would facilitate the delivery of a payload into
cells. Various hydrophobic modifications have been tried, including modification with cho‐
lesterol, myristate, dodecyl iodide, hexadecyl iodide, palmitic acid, oleic acid, stearic acid,
and phosphatidylcholine. In a recent study, Sawant et al. developed the synthesis and char‐
acterization of a PEI-DOPE conjugate, which was explored for gene delivery in vitro. The
modification with  DOPE strongly  increased the  transfection efficiency of  low molecular
weight PEI-1.8 kDa without any negative effects on its low cytotoxicity. The PEI-PE conju‐
gate was synthesized by reacting a phospholipid with low molecular weight PEI (PEI-1.8).
It was assumed that a PEI-PE conjugate would condense DNA due to the electrostatic in‐
teraction  between polycationic  PEI  moieties,  while  the  lipid  moieties  would  help  to  in‐
crease cell  interaction of the complexes and facilitate their incorporation into lipid-based
micellar systems via hydrophobic interactions [Sawant et al., 2012].
In order to take the advantages of both polycationic polymers and liposomes, Nie et al. have
constructed programmed lipopolyplexes, featuring well compacted DNA by PEI and liposome
complexing. Liposomes contain the helper lipid DOPE and a pH-cleavable PEG-hydrazone-
cholesterol conjugate for shielding. Lipopolyplexes composed of DNA condensed with PEI,
phospholipids including dioleoyl phosphatidyl ethanolamine (DOPE) and pH-labile ω-2-
pyridyldithio polyethylene glycol α-succinimidylester (OPSS)-PEG-HZN-Chol and yielded
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particles of 160 nm size and a zeta potential of +7 mV. Pyridylhydrazone-based Chol-PEG was
included in the liposomes for shielding in extracellular compartments and dynamic deshield‐
ing in acidic conditions such as in endosomes. In addition, this cholesterol-PEG derivative
contained also a pyridyldithio moiety to provide the possibility of coupling thiol-functional‐
ized compounds, such as receptor ligands [Fig. 1B.; Nie et al., 2011].
The endosome-escape potential of poly-histidine increases their use for delivery of nucleic
acids. The imidazole ring within histidine is a major component. Under the action of an
acidic endosomal interior, the weak basic nature of the imidazole ring with pKa around 6
allows its protonation and acquires cationic charges which trigger the destabilization of en‐
dosomal membranes. Accumulation of histidine residues within endosomes could elicit a
proton sponge effect and destroy endosomes as a result of their increased osmolarity. Both
chemistry conjugation and genetic engineering have produced a series of histidine-rich pol‐
ymers and peptides as well as lipids with imidazole, imidazolinium or imidazolium polar
heads. These histidylated carriers have been used to deliver nucleic acids including pDNA,
mRNA or siRNA duplex in vitro and in vivo with increased transfection efficiency [Midoux
et al., 2007; Martin and Rice, 2007].
The histidine-rich peptide H5WYG is a derivative of the N-terminal sequence of the HA-2
subunit of the influenza virus hemagglutinin in which five of the amino acids have been re‐
placed with histidine residues. H5WYG is able to selectively destabilize membranes at a
slightly acidic pH as the histidine residues are protonated. An anionic derivative of this
peptide, E5WYG, in which the histidines are replaced by glutamic acid residues, is com‐
pletely ineffective at membrane permeabilization at a pH= 6.8, while H5WYG can disrupt
50% of cells at pH= 6.8 and 97% of cells at pH= 6.2 within 15 minutes. H5WYG was also
able to retain its activity in the presence of serum, making it possible for use in vivo. The
most well-known non-viral  DNA condensing agent is  poly-L-lysine.  However,  PLL only
exhibits modest transfection when used alone and requires the addition of an endosomolyt‐
ic agent such as chloroquine or a fusogenic peptide to allow for release into the cytoplasm.
To increase the transfection efficiency of polylysine without the addition of membrane-dis‐
rupting agents, a histidine-substituted polylysine can be constructed that is able to become
cationic at endosomal pH [Martin and Rice, 2007].
In an attempt to facilitate endosome escape, many strategies have been developed to mimic
the viral mechanism for endosome destabilization. Viruses have acquired efficient solutions
for escaping from the maturating acidifying endosomes. For example, glycoproteins of
enveloped viruses contain hidden fusion peptides which are exposed after endocytosis, to
trigger fusion of the viral with the endosomal membrane [Wagner, 2011]. It is well-established
that the influenza virus utilizes the pH-sensitive membrane-destabilizing Hemagglutinin
protein (HA2) displayed on the viral coat to disrupt the endosomal membrane and enter the
cytoplasm. Hemagglutinin and other fusion proteins are characterized by their unique ability
to switch from an ionized and hydrophilic conformation at physiologic pH to a hydrophobic
and membrane-active one in response to acidic endosomal pH gradients, which destabilizes
the endosomal membrane leading to leakage of endosomal contents into the cytoplasm [Lin
et al., 2010]. At neutral pH, the HA2 subunit adapts a non-helical conformation due to charge
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repulsion arising from ionization of glutamic and aspartic acid residues. Within the interior of
the acidic endosomal compartment, however, the HA2 subunit transitions into a stable helical
secondary structure due to the protonation of glutamic and aspartic acids. The hydrophobic
and hydrophilic faces of the helical conformation favor endosomal membrane destabilization.
Endocytosed non-enveloped viruses such as rhinovirus or adenovirus expose lytic domains
which directly disrupt the endosomal membrane, either (in case of rhinovirus) generating a
pore large enough for crossing of the viral RNA strand into the cytoplasm or (in case of
adenovirus) disrupting the whole endosome. Such lytic domains have been utilized in artificial
settings as synthetic peptides for endosomal escape of polyplexes [Wagner, 2011].
Synthetic peptides mimicking a virus’s fusogenic peptides have also been designed for
delivery of nucleic acids. The amphipathic peptide, GALA, was synthesized with 30 amino
acid residues with a repeated amino acid sequence (e.g., glutamic acid-alanine-leucine-
alanine) that demonstrated pH sensitive fusogenic properties. A GALA peptide with a
formulation based on DNA/cationic liposome/ Transferrin (Tf) complexes induced enhanced
gene transfection. It is assumed that Tf-triggered internalization of the complexes by receptor-
mediated endocytosis and the GALA peptide promoted endosomal destabilization and release
of the genetic material into the cytoplasm [Park et al., 2010].
Modification of multifunctional envelope-type nano-devices (MENDs) with GALA peptide
facilitating endosomal escape, leads to the enhanced transfection efficiency of pDNA and
siRNA duplex in vitro and in vivo. To mimic envelope-type virus-like delivery systems, Sasaki
et al. developed an artificial nanocarrier system termed as a MEND, which consists of a
condensed DNA nanoparticle and lipid envelope which is further equipped with Tf, Choles‐
terol-GALA (Chol-GALA), or PEG-GALA to achieve target specificity and controlled intra‐
cellular trafficking, especially endosomal escape. As GALA can show fusogenic activity only
at acidic pH, the direct fusion of MEND with the plasma membrane is feasible only after
internalization. The Tf-MEND introduced with Chol-GALA or PEG-GALA showed a ten-fold
higher transfection than that displayed by Tf-MEND. However, the simultaneous introduction
of Chol-GALA and PEG-GALA enhanced the transfection efficiency more than 100-fold as
compared to Tf-MEND mediated transfection. Chol-GALA and PEG-GALA operated synerg‐
istically to destabilize the envelope and endosomal membranes, respectively. Chol-GALA
interacted with the envelope membrane whereas PEG-GALA penetrated into the endosomal
membrane, which could destabilize the membranes and induce fusion [Sasaki et al., 2008].
A cationic counterpart of GALA is the peptide KALA which is formed by substitution of the
alanine of GALA with lysine and a decrease in content of glutamic acid. KALA was the first
designed peptide that could bind DNA, destabilize membranes, and mediate significant gene
delivery. KALA undergoes a pH-dependent amphipathic α-helix to random coil conforma‐
tional change, when the environmental pH decreased from 7.5 to 5.0. KALA can deliver both
ODN and pDNA into cells [Park et al., 2010].
Several groups have focused their efforts on the development of synthetic, polymeric carriers
that mimic the endosomolytic properties of fusogenic proteins and enhance the cytoplasmic
delivery of therapeutic macromolecules. Recently, the ability of natural phospholipids to self-
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assemble into organized membrane-enclosed structures has been mimicked by amphiphilic
co-polymers. The combination of a hydrophobic monomer and an ionizable co-monomer that
has a more hydrophilic nature is one of the interesting strategies that have been adopted
frequently for pH-responsive gene delivery. A change in pH and subsequent adjustment in
the net charge causes the phase transformation depending on the hydrophobic and hydrophilic
balance of the copolymer. These synthetic amphiphiles form assemblies that are remarkably
similar to biological analogues, such as vesicles. Polymeric amphiphiles have much higher
molecular weights than phospholipids and can self-assemble into more entangled membranes,
imparting improved mechanical properties to the final structure [Park et al., 2010]. Polymer
vesicles or polymersomes can combine several different polymeric compositions provided that
they have the correct hydrophile/hydrophobe ratio. Particularly interesting for biomedical
applications, are those copolymers that combine hydrophobic blocks with the non-antigenic
properties of either PEG or biomimetic poly (2-(methacryloyloxy) ethyl phosphorylcholine)
(PMPC). Indeed, the macromolecular nature of such polymersomes offers several advantages
as compared to low-molecular-mass amphiphilic systems such as liposomes. PEG or PMPC
polymersomes can be decorated by denser and higher molecular mass hydrophilic polymeric
corona, with consequent longer circulation times than more traditional delivery systems such
as stealth liposomes and other nanoparticles. Typical examples are the copolymers of methyl
methacrylate (MMA) with methacrylic acid (MAc) or dimethylaminoethyl methacrylate
(DMAEMA). The MMA is the hydrophobic section while MAc is the hydrophilic part of the
chains. MAc is more hydrophilic at high pH when the carboxylic groups (COOH) are depro‐
tonated, but becomes more hydrophobic when the carboxylic groups are protonated. The
phase change occurs around the pKa value of the carboxylic groups, which is around 4.5-5.5.
The copolymers of MMA with DMAEMA, which are hydrophilic at low pH, when the amino
groups are protonated, but more hydrophobic when the amino groups are deprotonated. The
key feature of these polymers is their ability to directly enhance the intracellular delivery of
DNA, by destabilizing biological membranes in response to pH changes within the vesicular
compartment [Park et al., 2010].
These copolymers are characterized by their unique ability to “sense” the changes in environ‐
ment pH where they undergo a change from a hydrophilic, stealth-like conformation at
physiologic pH to a hydrophobic and membrane-destabilizing one in response to acidic
endosomal pH gradients [Lin et al., 2010]. Poly(ethylacrylic acid) (PEAA) is the first reported
polymer to display a pH-dependent disruption of synthetic lipid vesicles at acidic pH= 6.3 or
lower. The family of poly (alkyl acrylic acid) like poly (methyl acrylic acid) (PMAA), poly (ethyl
acrylic acid) (PEAA), poly (propyl acrylic acid) (PPAA), and poly (butyl acrylic acid) (PBAA)
were provided with pH-dependent, membrane destabilizing activities. These polymers are
hydrophilic and stealth-like at physiological pH, but become membrane-destabilizing after
uptake into the endosomal compartment where they enhance the release of therapeutic cargo
into the cytoplasm [Lin et al., 2010].
Diblock copolymers PMPC-PDPA as biomimetic polymersomes were used for gene delivery
made of pH-sensitive poly (2-(methacryloyloxy) ethyl-phosphorylcholine)-co-poly (2-
(diisopropylamino) ethyl-methacrylate) (PMPC-PDPA) diblock copolymers. The high bio‐
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compatibility features are ascribed to PMPC residue whereas the PDPA block imparts pH
responsiveness. These diblock copolymers exist as stable vesicles at physiological pH but these
vesicles rapidly dissociate at around pH= 5-6 to form unimers. The phase transition of vesicles
to unimers takes place because of protonation of the tertiary amine groups of PDPA chains,
which transforms hydrophobic PDPA chains into a hydrophilic entity from physiological pH
to mild acidic conditions. pH-responsive PMPC-PDPA vesicles release their contents upon
exposure to the low pH (5.5) media in endosomes or lysosomes [Lomas et al., 2007].
Comb-like diblock copolymers with a robust membrane-destabilizing activity in response
to  a  mildly  acidic  pH in  the  endosome were  also  developed.  Acid-cleavable  hydrazone
linker has also been frequently utilized to achieve the facilitated release of nucleic acids
from  polyplexes.  The  first  pH-sensitive  block  was  the  copolymer  of  ethyl  acrylic  acid
(EAA) and hydrophobic methacrylate, and the second block was the copolymer of hexyl
methacrylate (HMA) and trimethyl aminoethyl methacrylate (TMAEMA) grafted with N-
acryloxy succinimide or β-benzyl L-aspartate N-carboxy-anhydride via acid-cleavable hy‐
drazone  linkages.  These  comb-like  polymers  exhibited  a  high  concentration-dependent
hemolytic activity in acidic solutions and degraded into smaller fragments via acid-hydrol‐
ysis of hydrazone linkages, resulting in minimized toxicity and facilitated elimination by
renal  excretion in vivo.  These polymers formed siRNA complexing polyplexes that  were
stable even in the presence of serum and nucleases, and efficiently silenced GAPDH ex‐
pression in MCF-7 breast cancer cells in vitro [Lin et al., 2010].
8.1.3. Low pH-sensitive siRNA/ODN–polymer conjugates
Small interfering RNA (siRNA)-based therapies have great potential for the treatment of
diseases such as cancer, but an effective delivery strategy for siRNA is unclear. Benoit et
al. developed a ternary pH responsive endosomolythic complex for the delivery of siRNA
in order  to  sensitize  drug-resistant  ovarian cancer  cells  to  doxorubicin.  The electrostatic
complexes were self-assembled by cationic micelles used as a nucleating core, siRNA and
a pH-responsive endosomolytic polymer. Cationic micelles were formed from diblock co‐
polymers  of  dimethylaminoethyl  methacrylate  (pDMAEMA)  and  butyl  methacrylate
(pDbB).  The  hydrophobic  butyl  core  mediated  micelle  formation  while  the  positively
charged pDMAEMA corona enabled siRNA condensation. To enhance cytosolic delivery
through endosomal release, a pH-responsive copolymer of poly (styrene-alt-maleic anhy‐
dride) (pSMA) was electrostatically complexed with the positively charged siRNA/micelle
to form a ternary complex. Complexes exhibited size (30-105 nm) and charge (slightly pos‐
itive) properties and mediated uptake in > 70% of ovarian cancer cells after 1 h of incuba‐
tion [Benoit et al.,  2010].  The optimized formulation of the resulting ternary nano-vector
were used to deliver siRNA against polo-like kinase 1 (plk1), a gene up-regulated in many
cancers  and  increased  doxorubicin  sensitivity  in  the  drug-resistant  ovarian  cancer  cells.
Sensitization occurred through a p53 signaling pathway, as indicated by caspase 3/7 up-
regulation following plk1 knockdown and doxorubicin treatment, and this effect could be
abrogated using a p53 inhibitor. To demonstrate the potential for dual delivery from this
polymer system, micelle cores were subsequently loaded with doxorubicin and utilized in
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ternary complexes to achieve cell sensitization through simultaneous siRNA and drug de‐
livery from a single carrier. These results show that knockdown of plk1 results in sensiti‐
zation of multi-drug resistant cells to doxorubicin, and this combination of gene silencing
and small molecule drug delivery may prove useful to achieve potent therapeutic effects
[Benoit et al., 2010].
Acid-degradable and targetable polyion complex (PIC) micelles increased the gene silencing
in hepatoma cells. This multi-functional carrier was synthesized by assembling lactosylated-
PEG-siRNA conjugates via acid-labile β-thiopropionate linkages into PIC micelles through the
mixing with poly (L-lysine). The lactosylated-PEG-siRNA/PLL polyplexes were successfully
transported into hepatoma cells in a receptor-mediated manner, releasing hundreds of active
siRNA molecules into the cellular interior responding to the pH decrease in the endosomal
compartment. This carrier exhibited almost 100 times enhancement in gene silencing activity
and facilitating the practical utility of siRNA therapeutics [Oishi et al., 2005].
8.2. Redox-responsive nanocarriers
One of the several micro-environmental features, which have been widely exploited for
improving the efficiency of nucleic acid delivery, is the redox potential gradient existing
between extracellular environment and various subcellular organelles in normal as well as
pathological states. The existence of a high redox potential gradient between oxidizing
extracellular space and the reducing environment of subcellular organelles has been exploited
mainly by incorporating a disulfide bond(s) into the structure of the delivery vectors to provide
them with a capability to release the therapeutic nucleotides selectively in the subcellular
reducing space. The original interest in gene delivery systems controlled by redox potential
gradients was guided by the need to transiently enhance stability of the vectors during the
delivery [Cheng et al., 2011; Meng et al., 2009].
The design of reduction-sensitive polymers and conjugates usually involves incorporation
of disulfide linkage(s) in the main chain, at the side chain or the cross-linker in the struc‐
ture of the polymers of either linear or branched structure. There are only a few examples
of polyplexes where the disulfide bonds are associated with the nucleic acids [Soundara
Manickam and Oupický, 2006]. Reduction-sensitive polymers and conjugates are character‐
ized by an excellent stability in the circulation and in extracellular fluids, whereas they are
prone to rapid degradation under a reductive environment present in intracellular com‐
partments such as the cytoplasm and the cell nucleus at a time scale from minutes to hours,
through thiol-disulfide exchange reactions. This quick-response chemical degradation be‐
havior is distinct from common hydrolytically degradable polymers such as aliphatic poly‐
esters and polycarbonates in which the ester and carbonate bonds usually exhibit gradual
degradation kinetics inside body with degradation times ranging from days to weeks/or to
months. This remarkable feature renders them extremely for the controlled cytoplasmic de‐
livery of a variety of bioactive molecules including DNA, siRNA, antisense oligonucleotide
(ODN), proteins, drugs, etc [Du et al., 2010].
Disulfide bonds present in the structure of polyplexes are readily reduced in the reducing intra‐
cellular environment, while largely preserved in the predominantly oxidizing extracellular
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space. The intracellular reduction of disulfide bonds is most likely mediated by small redox mol‐
ecules like glutathione (GSH) and thioredoxin, either alone or with the help of redox enzymes.
Glutathione tripeptide (g-glutamyl-cysteinyl-glycine; GSH) is the most abundant intracellular
sulfhydryl present in millimolar concentrations inside the cell but only in micromolar concentra‐
tions in the blood plasma and GSH/glutathione disulfide (GSSG) is the major redox couple in ani‐
mal cells [Meng et al., 2009]. Glutathione has multiple direct and indirect functions in many
critical cellular processes like synthesis of proteins and DNA, amino acid transport, enzyme ac‐
tivity, metabolism and protection of cells. Glutathione also serves as a reductant by functioning
to destroy the free radicals, hydrogen peroxide and other peroxides. It also functions as a storage
form of cysteine. The intracellular glutathione concentration is an additive function of both the
oxidized (GSSG) and the reduced forms (GSH) of glutathione. The glutathione redox ratio is
maintained and determined by the activity of glutathione reductase, NADPH concentrations
and transaldolase activity. The redox state of the GSH/GSSG couple is often used as an indicator
of the overall redox environment of the cell. The large difference in reducing potential between
the intracellular and extracellular milieu may be exploited for triggered intracellular delivery of
a variety of bioactive molecules including DNA, siRNA, antisense oligonucleotide (ODN), pro‐
teins and low molecular weight drugs. Furthermore, of particular interest is that tumor tissues
are highly reducing and hypoxic compared with normal tissues, with at least 4-fold higher con‐
centrations of GSH in the tumor tissues over normal tissues, rendering the reducible bioconju‐
gates valuable for tumor-specific drug and gene delivery [Meng et al., 2009]. Some examples are
mentioned for the use of redox responsive nanocarrier in below:
8.2.1. The use of responsive sensitive nanocarrier for the stabilization of the carrier and decrease the
cytotoxicity
A prerequisite for every systemic nucleic-acid delivery system is stability in the blood stream
prior to reaching its target cell. Therefore, the carrier must prevent the premature release of its
load. In order to enhance the stability of the delivery system, either the surface of the carriers
was crosslinked, or the low-molecular-weight materials were sulfhydryl polymerized. Pepti‐
des containing many lysines and histidines were used for the complexation of nucleic acids,
while cysteines were introduced to obtain stable and reductively degradable carriers. A series
of different vehicles was built from sequences of many lysines, tryptophan, and a variable num‐
ber of cysteines. All peptides obtained were able to condense DNA into particles, and exhibited
increased stability after disulfide formation. The disulfide crosslinked carriers conveyed 5- to
60-fold higher gene expression as compared to their non-crosslinked analogs. The degree of
gene expression was dependent on the number of incorporated cysteines, with a maximum for
terminally inserted cysteines. The modification of the e-amino groups of pLL with 3-(2-aminoe‐
thyldithio) propionyl residues or their crosslinking with Dimethyl 3,3-dithiobispropionimi‐
date (DTBP) comprises another approach utilizing reductively degradable gene carriers. These
molecules were able to complex nucleotides into particles that were stable under physiological
conditions but disintegrated upon treatment with GSH [Meng et al., 2009].
Read et al. prepared gene delivery vectors based on reducible polycations (RPCs) by oxidative
polycondensation of the peptide Cys-Lys10-Cys and used to condense nucleic acids. The
Novel Gene Therapy Approaches230
release of nucleic acids in these vectors relied on cleavage of the RPC in the reduced intracel‐
lular environment, eliminating the toxicity associated with high molecular weight polymers.
However these polymers rely on chloroquine or cationic lipids to enhance endosomal escape
and mediate transfection [Read et al., 2003].
Low molecular weight DNA condensing polypeptides were developed by substituting one to
four lysine residues of Cys-Trp-Lys18 (CWK18) with cysteine groups. These polypeptides
could spontaneously oxidize to form interpeptide disulfide crosslinks after binding to plasmid
DNA, resulting in small stabilized DNA condensates. These reversibly cross-linked polypep‐
tide DNA condensates were 5-60-fold more potent at mediating gene expression in HepG2
and COS-7 cells as compared to the un-crosslinked alkylated CWK18 (AlkCWK18) DNA
condensates [Fig. 2 A; McKenzie et al., 2000]. In another study, in order to improve the
endosomolytic properties, Histidine containing reducible polycations based on CH6K3H6C
monomers (His6 RPCs) was developed, which are highly effective DNA transfection agents,
provided sufficient buffering capacity and enhanced in vitro gene expression with rapid
unpackaging following reduction in the cytoplasm without aid of chloroquine, an agent that
promotes endosomal escape [Stevenson et al., 2008].
High molecular weight polypeptides containing disulfide bonds in the backbone were
synthesized by an oxidative copolymerization of a histidine-rich peptide (HRP) and a nuclear
localization sequence (NLS) peptide derived from the importin α-binding SV40 T antigen
sequence. The synthetic approach allowed an easy synthesis of reducible copolypeptides
(rCPP) with different relative contents of the HRP and NLS sequences. The rCPPs were
synthesized by DMSO-mediated oxidative polycondensation. To combine two functional
peptides into a single polymeric carrier, multiblock reducible copolypeptides were synthe‐
sized by randomly connecting HRP and NLS peptides via disulfide bonds into a linear
polypeptide chain. Mild oxidation of the terminal Cys residues with DMSO was used. The
copolypeptides show minimal cytotoxicity and transfection activity comparable to or better
than control PEI polyplexes [Manickam and Oupický, 2006].
Other  carriers,  such  as  chitosan  (deacetylated  chitin)  were  also  stabilized  via  disulfide
bonds. For this purpose, the primary amino groups of low-molecular-weight chitosan were
thiolated  with  2-iminothiolane.  These  modified  polymers,  such  as  chitosanthiobutylami‐
dines, were mixed with pDNA to form coacervates in the nanometer range [Bauhuber et
al., 2009]. In a recent study, Ho et al. modified chitosan (CS) with extending arms consist‐
ing of disulfide spacers and arginine (Arg) residues (CS–SS–Arg) as a novel non-viral carri‐
er for gene delivery. Cleavage of disulfide spacers by glutathione (GSH) and dithiothreitol
due to thiol-disulfide exchange reactions indicates that CS–SS–Arg is likely reducible in cy‐
toplasm. The CS–SS–Arg was allowed to condense GFP DNA to form self-organized nano‐
particles with a diameter of 130 nm and zeta potential of 35 mV. The DNA was released
from CS–SS–Arg/ DNA nanoparticles over time in the presence of GSH and the results sug‐
gest that the Arg-rich bioreducible CS–SS–Arg/ DNA nanoparticles are promising as a car‐
rier for gene delivery [Ho et al., 2011].
A dilemma in non-viral nucleic acid delivery is demonstrated by considering the polymeric
transfection agent PEI, which is often referred to as the gold standard for polymer-based
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gene carriers due to the relatively high transfection efficacy of its polyplexes. Unfortunate‐
ly,  efficacy and adverse reactions seem to be strongly associated with the use of PEI.  A
popular strategy to reduce the toxicity of polyplexes is to use low MW polycations or cati‐
onic monomers that are less cytolytic, and crosslink them with agents that can be cleaved
or activated by the intracellular environment. Numerous reports describe the synthesis of
carrier systems containing disulfide bonds that allow for a compaction and protection of
the nucleic acid in the extracellular environment accompanied by reduced toxicity due to
intracellular polymer degradation. Peng et al. prepared thiolated PEI (800 Da) to further ox‐
idize into disulfide cross-linked PEI (PEI-SS),  with average molecular weights of 7.1,  8.0
and 8.4 kDa depending on the degree of thiolation. Those PEI-SS had lower cytotoxicities
and higher transgene expressions compared with that of the 25-kDa branched PEI (bPEI)
[Peng et al., 2008].
Figure 2. A) Cross-linked peptide-DNA condensates: Formation of peptide-DNA condensates through ionic binding
of the peptide to the pDNA followed by interpeptide oxidation; Stabilization of the DNA condensates by reversible
disulfide bonds. B) A novel stimuli-sensitive liposome: This carrier composes of cationic peptides (e.g., Arginine oc‐
tamer) and detachable coat (e.g., PEG) for the intracellular gene or drug delivery
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Kang et al. synthesized reducible polycations (RPC) that degrade due to changes in the in‐
tracellular reduction potential from low molecular weight (MW) bPEI 0.8 kDa via thiola‐
tion and oxidation.  In  this  study,  2-iminothiolane was used to  create  thiol  groups from
primary amines. In this approach, a primary amine reacts with 2-iminothiolane to yield a
thiol group and an amidine moiety. A procedure based on the use of 2-iminothiolane was
employed in order to avoid problems associated with the use of DTBP. As a result, unlike
other thiolation methods, by converting primary amines to amidine groups, the number of
positive charges in the final product at a neutral pH was preserved. Moreover, the newly
generated amidines contribute to the electrostatic condensation of nucleic acids. The cyto‐
toxicity of RPC-bPEI 0.8 kDa was 8-19 times less than that of the gold standard of polymer‐
ic transfection reagents, bPEI 25 kDa. In general, the toxicity of High MW (HMW) PEI is
greater than that of Low MW (LMW) PEI because HMW PEI interacts more effectively with
components that are essential for cell survival such as intracellular membranes, vital pro‐
teins,  and  nucleic  acids  than  its  LMW  counterpart.  Thus,  the  reduced  cytotoxicity  of
HMWRPC-bPEI 0.8 kDa may be due to the degradation of the polymer in the intracellular
environment after cellular uptake [Kang et al., 2011].
In another study, Son et al developed a multi-functional gene carrier based on thiolated low
molecular weight bPEI with functional moieties for cytoplasm-sensitive reduction, tumor
targeting, and prolonged circulation in blood. The bPEI was modified with α-maleimide-ω-
N-hydroxysuccinimide ester polyethylene glycol (MAL-PEG-NHS, MW: 5000) and cyclic NGR
peptide for enhanced blood compatibility and tumor targeting ability. The resulting polymer
(bPEI-SS-PEG-cNGR) exhibited DNA condensing capacity, a reducing property, and im‐
proved tumor targeting, suggesting that the multifunctional polymer constitutes a promising
non-viral vector for cytoplasm- and tumor-specificities [Son et al., 2010].
8.2.2. Disulfides for the attachment of a shielding moiety
DOPE and N-[2-methoxypoly (ethylene glycol)-α-aminocarbonylethyl-dithiopropionate]
formed a liposome that was covalently coupled to distearoylphosphatidylethanolamine
(mPEG-SS-DSPE). The incorporation of the mPEG-SS-DSPE stabilized these liposomes at low
pH, but the stabilizing effect was quickly reversed when the carrier was incubated with either
DTT or cell-free extracts. Under these conditions, the disulfides were reduced, and thus the
protecting PEG chains were cleaved, and the vehicle became degradable at low pH, releasing
its load. Disulfides were used for the formation of copolymers consisting of bPEI 25 kDa and
PEG of 20 or 30 kDa. The connection of PEG via DSPE led to a 125% increase in blood levels
and decreased hemolysis compared to bPEI 25 kDa [Bauhuber et al., 2009].
Polyion  complex  (PIC)  micelles  are  self-assembling  particles  with  a  core-shell  structure
formed by complexation between a pair of oppositely charged polymers having hydrophil‐
ic PEG segments. They can be utilized as gene delivery vectors with high water-solubility
and colloidal stability, employing negatively charged genetic materials and cationic poly‐
mers. One approach to enhance the stability of PIC micelles is glutathione (GSH)-sensitive
stabilization of PIC micelles with the core cross-linked through disulfide bonds, composed
of antisense oligonucleotide and thiolated PEG-PLL block copolymer. The micelles showed
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sufficient colloidal stability due to the PEG shell and core cross-linking. Moreover, ODN
entrapped in the micelles also displayed highly increased stability against nuclease, com‐
pared to that in the micelles without cross-linking. Release of ODN from the dissociated
micelles at intracellular GSH concentration suggested the potential for intracellular ODN
delivery. It is reported that PEG-peptide (PEG-SS-Cys-Trp-Lys(18): PEG-SS-CWK18) having
disulfide cross-linker displayed much enhanced gene transfer efficiency compared to PEG-
peptide having non-reducible cross-linker (PEG-VS-CWK18) when complexed with plas‐
mid DNA [Kim and Kim, 2011].
8.2.3. Disulfides for the attachment of a targeting moiety
For a successful accumulation of the nucleic acid in the target cell, the delivery system requires
the attachment of a specific “recognition element”. However, since many targeting moieties
are rather large, they hinder effective unpacking of the gene vector. Thus, inside cells, it is very
important to remove them to facilitate the disassembly of the load. Here, disulfides can be
quite useful, as they can be cleaved at the cell surface during cellular entry or in the cytosol
[Bauhuber et al., 2009]. The frequency of sulfhydryl occurrence in Antibodies/proteins or other
molecules is usually low as compared to other groups like amines or carboxylates. The use of
sulfhydryl reactive chemistries thus can restrict modification to only a limited number of sites
within a target molecule. N-Succinimidyl 3-(2-pyridyldithio) propionate (SPDP) is one of the
most popular heterobi-functional cross-linking agents. The NHS ester end of SPDP reacts with
amine groups to form an amide linkage, while the 2-pyridyldithiol group at the other end can
react with sulfhydryl residues to form a disulfide linkage. The reagent is also useful in creating
sulfhydryls in proteins and other molecules. Once modified with SPDP, a protein can be treated
with DTT (or other disulfide reducing agents, to release the pyridine-2-thione leaving group
and form the free sulfhydryl [Manjappa et al., 2011].
Iminothiolane  (Traut's  reagent)  can  react  with  primary  amines  in  a  ring-opening  reac‐
tion  that  regenerates  the  free  sulfhydryl.  An  example  is  the  thiolation  of  antibody  us‐
ing Traut's  reagent  in  the  preparation of  immunoliposomes.  It  is  an excellent  thiolation
reagent  for  use  in  the  preparation  of  immunotoxins.  It  has  also  been  used  to  modify
and  introduce  sulfhydryls  into  oligosaccharides  from  asparagines  linked  glycans  [Man‐
jappa et  al.,  2011].
8.2.4. Disulfide bonds to enhance the intracellular release of the nucleic acid
SiRNA has generated great interest as a research tool and a therapeutic agent because of
its ability to efficiently silence specific genes by the mechanism of RNA interference [Vi‐
dugirienė  et  al.,  2007].  However,  siRNA  cannot  penetrate  the  cellular  membrane  alone
and can be easily degraded by RNase; therefore, effective siRNA carriers are needed for
siRNA-based  therapies.  In  this  regard,  poly  ion  complexes  (PICs)  formed  from  nucleic
acids and oppositely charged polycations have been widely studied as a promising nucle‐
ic acids carrier because of the variety of chemical designs of polycations. PICs protect nu‐
cleic  acids from enzymatic  degradation and show facilitated cellular  uptake.  Thus,  PICs
have demonstrated to be useful for plasmid DNA (pDNA) delivery in vitro  and in vivo.
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Nevertheless, there has been limited success to date in the development of PICs for siR‐
NA delivery. In general, PICs from monomeric siRNA, which has a short structure com‐
pared  to  pDNA,  lack  stability  under  the  physiological  condition;  therefore,  substantial
stabilization of PICs is essential to successful siRNA delivery. Meanwhile, after PICs inter‐
nalize and reach the cytoplasm, they are required to efficiently release siRNA to exert its
gene silencing effect. To complete such variable properties, considerable efforts have been
dedicated  to  the  design  and  chemical  modification  of  polycations  [Yu-Lin  et  al.,  2011].
Takemoto et  al.  reported a  new class  of  chemically  modified siRNA, i.e.,  siRNA-grafted
poly (aspartic acid) [PAsp (-SS-siRNA)], for PIC based siRNA delivery. PAsp (-SS-siRNA)
consists of a backbone of a poly (aspartic acid) [PAsp] derivative and grafted siRNAs via
a disulfide linkage. The siRNA-grafted polymer formed stable PICs due to its larger num‐
bers and higher density of anionic charges compared with monomeric siRNA, leading to
effective internalization by cultured cells. Following the endosomal escape of the PIC, the
disulfide linkage of the siRNA-grafted polymer allowed efficient siRNA release from the
PIC under intracellular reductive conditions. Consequently, the PIC from the siRNA-graft‐
ed polymer showed a potent gene silencing effect without cytotoxicity or immunogenici‐
ty, demonstrating a promising feature of the siRNA-grafted polymer to construct the PIC-
based nanocarrier for in vivo siRNA delivery [Takemoto et al., 2010].
The conjugation of nucleic acids including siRNA and antisense oligodeoxynucleotide to
polymer such as PEG and hyaluronic acid through a disulfide bond represents a approach
to construct GSH-responsive gene delivery systems [Cheng et al., 2011]. Lee et al. explored
the potential  possibility of  hyaluronic acid (HA) as a biocompatible,  biodegradable,  and
non-cytotoxic material for delivery of siRNA. Nano-sized HA hydrogels, called HA nano‐
gels,  were  prepared  for  target-specific  intracellular  delivery  of  siRNA  to  HA  receptor
over-expressing cancer  cells.  HA nanogels  crosslinked with disulfide linkages were pre‐
pared by an inverse emulsion method. An aqueous phase containing thiol functionalized
HA and siRNA was emulsified in an oil phase under ultrasonication, thus generating self
cross-linked HA nanogels encapsulating anti-green fluorescent protein (GFP) siRNA. Re‐
lease profiles of siRNA from HA nanogels were studied in response to various reductive
conditions that could cleave the disulfide linkages of HA nanogels to varying extents. The
HA/siRNA nanogels were readily taken up by HA receptor positive cells (HCT-116 cells)
having HA-specific CD44 receptors on the surface [Lee et al., 2007]. Kam et al. conjugated
various biological molecules, including oligonucleotides and siRNA, to phospholipid–PEG
functionalized single-walled carbon nanotube (SWNT) via cleavable disulfide linkage. Due
to the presence of a PEG linker, these SWNT conjugates form highly stable suspensions in
aqueous solutions including physiological  buffers.  The SWNT carriers mediated efficient
delivery and release  of  DNA and siRNA inside cells.  Gene silencing experiments  using
HeLa cells displayed a two-fold higher silencing efficiency compared to lipofectamine at
the same siRNA concentration. This is ascribed to a high surface area of SWNT for effi‐
cient siRNA cargo loading, high intracellular transporting ability of SWNT, and high de‐
gree  of  endosome/lysosome  escape  owing  to  the  disulfide  approach  [Kam  et  al.,  2005;
Meng et al., 2009].
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9. Stimuli-sensitive multi-functional nano-particulate nucleic acid delivery
systems
As mentioned in the previous sections, there are some conflicting demands for overcoming
different extra- and intracellular barriers met by nucleic acid-loaded nano-particles during
delivery. The delivery systems, which response to only one stimulus and have less function‐
ality, may not be efficient enough to achieve a satisfactory therapeutic effect in vivo. Natural
gene carriers, such as viruses, have developed sophisticated mechanisms and modular
biopolymer designs to overcome these barriers. The development of virus-mimicking, multi-
functional gene delivery systems with features that mimic virus modular components and
which transfect specific cell lines with high efficacy is considered to be a practical strategy in
the future, in particular for intravenous administration. Ideal polymer-based, nucleic acid-
loaded nanoparticles for potential in vivo applications should have several components that
function at the appropriate stages during the delivery. The hierarchical nature of the synthetic
carriers allows the incorporation of membrane-disrupting peptides, nucleic acid binding
components, a protective coat layer, and an outer targeting ligand all in a single nanoparticle,
but with functionality such that each is utilized in a specific sequence during the gene delivery
process [Du et al., 2010].
The ligands on the particle surface can be used to recognize a specific cell/tissue, and facilitate
cellular uptake through receptor-mediated endocytosis. A reversibly removable hydrophilic
pole, such as PEG chains, provides stealth protection of the nanoparticles during their
circulation in the blood as well as travelling through the ECM, and may reduce toxicity.
Moieties that are responsive to different stimulus must be combined to result in an appropriate
set of various trigger mechanisms at different time points. Such moieties might be cleaved in
acidic environments, show good buffering capacity, be redox active or enzymatically cleava‐
ble, the pole can be removed, which might enhance the cellular uptake and/or endosomal
escape. In the inner part of the nanoparticles, nucleic acids can be temporally loaded through
electrostatic interaction, covalent conjugation, or physical encapsulation, which will protect
the nucleic acid against enzymatic degradation. The inner part should be stable enough until
delivery to the correct site (cytoplasm and/or nucleus) where it is disassembled to release the
naked nucleic acid upon some kind of stimulus. In addition, it is preferred that the inner part
contains endosomolytic components that help the endosomal escape. If cell penetrating
peptide (CPP) is incorporated onto the surface of the inner part, cellular uptake may be further
improved [Du et al., 2010]. Many experimental results emphasize that the main obstruction of
CPPs is the absence of specific cellular delivery [Vivès et al., 2008]. Ideally, the design of a
smart delivery system should be built in such a way that during the first phase of delivery, a
non-specific cell-penetrating function is shielded by the function of cell-recognition motif
which favors the concentration of the drug at the targeted cell type. Upon accumulating in the
target, protecting polymer (or specific ligand) attached to the surface of the smart nanocarrier
via the stimuli-sensitive bond should detach under the action of local conditions and expose
the previously hidden second function (CPP) allowing for the subsequent delivery of the
carrier and its cargo inside cells [Torchilin, 2008]. Such engineering of smart nanodevices has
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been illustrated in the work by Sawant et al. who developed targeted long-circulating PEGy‐
lated liposomes and PEG-phosphatidylethanolamine (PEG-PE)-based micelles possessing
several functionalities. Such systems were capable of targeting a specific cell or organ by
attaching the monoclonal antibody to their surface via long PEG spacer groups. Second, these
liposomes and micelles were additionally modified with TATp moieties attached to the surface
of the nanocarrier by using TATp-short PEG-PE derivatives. PEG-PE used for liposome surface
modification or for micelle preparation was made degradable by inserting the pH-sensitive
hydrazone bond between PEG and PE (PEG-Hz-PE). Under normal pH values, TATp functions
on the surface of nanocarriers were ‘‘shielded’’ by long protecting PEG chains (pH-degradable
PEG 2000-PE or PEG 5000-PE) or by long para- nitrophenyl PEG-PE (pNP-PEG-PE) moieties
used to attach antibodies to the nanocarrier (non-pH degradable PEG3400-PE or PEG5000-PE).
Following prolonged circulation and uptake into the tumor mass mediated by both the
enhanced permeability and retention (EPR) effect and the active targeting agent on the surface
of the carrier, the pH responsive bonds are cleaved in the acidic environment of the tumor,
thereby releasing the high molecular weight PEG strands from the carrier and exposing the
Tat-peptide for enhanced intracellular uptake and intracellular target localization, specifically
located to the target tumor cells [Sawant et al., 2006; Torchilin, 2008].
Another example of a triggerable system was created by the synthesis of a liposomal carrier
that was comprised of a membrane-permeable ligand and a reductively detachable PEG
coating. The surface cover consisted of PEG coupled to DOPE via a thiolytically cleavable
linker, while the ligand, an ariginine octamer, was immobilized onto cholesteryl hemisuccinate
(CHEMS). These conjugates were mixed with dipalmitoylphosphatidylcholin (DPPC) and
unmodified DOPE to form liposomes. DOPE/mPEG–DTP–DSPE liposomes were stable in
plasma whereas in the presence of a reducing agent the PEG coating was effectively detached
off the liposomal surface, leading to vesicle destabilization and fusion as well as complete
release of the entrapped contents. Upon activation of the trigger, the arginine octamer would
be exposed, causing cellular uptake of the liposome. Once in the cytosol, the remaining
disulfide bonds would be cleaved, ultimately resulting in the destabilization the whole carrier
[Fig. 2B; Bauhuber et al., 2009].
10. Nanoparticles mediated brain delivery systems
Nanoparticles have emerged as potential drug delivery carriers to tissues throughout the body.
Yet passing the BBB is particularly difficult. The proper design of such engineered ‘nanocar‐
riers’ becomes very important in transversing the impermeable membranes to facilitate drug
delivery. At the same time, it is also required to retain the drug stability and ensure that early
degradation of drugs from the nanocarriers does not take place. Therefore, for drugs to be
successfully delivered to their target, many factors such as its size, biocompatibility, target
specific affinity, avoidance of reticuloendothelial systems, stability in blood, or ability to
facilitate controlled drug release need to be considered during manufacture of the NPs. As for
nanocarriers to serve as good candidates for drug delivery across the BBB can be summarized
as following [Bhaskar et al., 2010]: a) Particle diameter less than 100 nanometers; b) Non-toxic,
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biodegradable and biocompatible; c) Stable in blood (i.e., no opsonisation by proteins); d) BBB-
targeted (i.e., use of cell surface, ligands, and receptor mediated endocytosis); e) No activation
of neutrophils, non-inflammatory; f) No platelet aggregation; h) Avoidance of the reticuloen‐
dothelial systems; i) Prolonged circulation time; j) Scalable and cost effective with regard to
manufacturing process; m) Agreeable to small molecules, peptides, proteins or nucleic acids;
n) Controlled drug release or modulation of drug release profiles [Bhaskar et al., 2010].
One of the most important challenges in nano-based diagnostics and drug delivery is the
functionalization of nanoparticles. At first, the combination of effective conjugation strategies
is needed to develop, in a highly controlled way, specific biomolecules to the surface of
nanoparticles. Some of the most prominent candidate biomolecules are cell penetrating
peptides such as SynB vectors, penetratin and Tat that facilitate enhanced intracellular
delivery, fluorescent dyes (rhodamine, alexa, Cy5.5), tumoral markers for brain and gene
therapeutic agents for genetic therapy such as siRNA [Bhaskar et al., 2010].
Functionalization itself requires a profound knowledge of the target organ and its transport
mechanisms. The BBB has several transport molecules that can potentially increase the
efficiency and kinetics of nanocarriers towards brains such as, growth factors (e.g. epidermal
growth factor, vascular endothelial growth factor, basic fibroblast growth factor, insulin-like
growth factors (IGF-I and -II), biotin binding proteins (avidin, streptavidin, or neutravidin),
insulin, albumin, leptin, lactoferrin, iron binding protein p97 (melanotransferrin), transferrin
and Angiopep-2. Some agents play a pivotal role in enhancing the permeability of nanoprobes
through BBB. Moreover, by altering the surface of polymeric nanoparticles on coating them
with different hydrophilic surfactants, such as polysorbate 80 (Tween® 80) or other polysor‐
bates with 20 polyoxyethylene units, biocompatible coatings of non-viral gene delivery
systems, e.g. by PEG attachment for siRNA delivery show significant advantage in brain
targeting [Bhaskar et al., 2010].
11. Cell penetrating peptides as efficient delivery systems
Generally, the nucleic acid delivery techniques comprise various physical and chemical
methods, viral and non-viral vector systems, and uptake of naked nucleic acids [Veldhoen et
al., 2008; Bolhassani et al., 2011]. All of them have certain advantages and dis-advantages and
might only be appropriate if particular requirements are performed. For instance, physical and
chemical methods like microinjection, electroporation or particle bombardment as well as
calcium phosphate co-precipitation are highly efficient but rather harmful for the target cells
and lack the potential to be applicable in vivo. There is general agreement that viral vector
systems are the most efficient vehicles to deliver nucleic acids into cells [Veldhoen et al.,
2008]. However, despite substantial efforts over the last 15 years, up to now research has failed
to develop suitable and especially safe viral systems. As a result of the difficulties encountered
with these viral vectors (e.g., mutagenesis and immune responses), much attention was paid
to the development of safer non-viral delivery systems. Currently, liposomes and cationic
polymers are used as a standard tool to transfect cells in vitro. These approaches are yet
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characterized by a significant lack of efficiency accompanied by a high level of toxicity making
them mostly inadequate for in vivo applications [Veldhoen et al., 2008; Bolhassani et al., 2011].
Peptides acting as shuttles for a controlled cellular delivery of nucleic acids represent a new
concept to bypass the problem of poor bio-availability and clinical efficacy of such macromo‐
lecules [Veldhoen et al., 2008]. The idea of using peptides as carriers goes back some 20 years
when two groups discovered by chance that the HIV-1 transactivating protein Tat is taken up
by mammalian cells [Frankel and Pabo, 1998; Green and Loewenstein, 1988]. Just a few years
later, the Antennapedia homeodomain of Drosophila melanogaster was shown to act similarly
[Joliot et al., 1991]. Then, it could be shown that peptides derived from Tat and Antennapedia
as well as other proteins are capable of transporting macromolecular cargo molecules into cells
[Fawell et al., 1994; Schwarze et al., 1999]. Based on such promising results, a rapidly expanding
field focusing on the so-called cell-penetrating peptides (CPPs), also referred to as protein
transduction domains (PTD) began to develop [Veldhoen et al., 2008].
Up to now numerous CPPs have been described. According to their origin, they can be grouped
into three classes. The first group contains CPPs originating from naturally occurring proteins
“protein derived CPPs”, the second consists of chimeric CPPs composed of different protein
domains and the third class includes so-called “model CPPs” which were developed according
to structure-fuction relationships without any homology to natural sequences. All known
CPPs are basic amino acids causing a net positive charge at physiological pH [Langel, 2002].
At present, a peptide is considered a CPP, if it shows the ability to cross a biological membrane.
A cargo can be bound to the CPP covalently or non-covalently. Covalent attachment can be
achieved either by expression as a fusion construct or by chemical coupling [Zatsepin et al.,
2005]. In some cases, cargo and carrier bind each other non-covalently through ionic interac‐
tions. Depending on the nature of both binding partners assembly of nanoparticles may occur
[Veldhoen et al., 2008].
The studies have shown that the cargo-CPP complexes are taken up by directly penetrating
the cell membrane or by an endocytotic pathway. However, the precise mechanism of
internalization remains elusive and strongly depends on the properties of both CPP and cargo
as well as the transfection conditions and the cell lines used [Maiolo et al., 2005; De Coupade
et al., 2005; El-Andaloussi et al., 2007; Bolhassani, 2011]. Recent studies indicate that the uptake
mechanism of CPPs can be influenced by the attachment of cargo. For example, Richard et al.
[Richard et al., 2003; Richard et al., 2005] reported a co-localization of Tat 48-59 with markers of
clathrin-mediated endocytosis, whereas Fittipaldi et al. [Fittipaldi et al., 2003] found a caveolae/
lipid raft-dependent process for a Tat-GFP fusion protein and Wadia et al. [Wadia et al., 2004]
described a macropinocytotic uptake pathway for a fusion construct of Tat peptide with Cre
recombinase.
However, further information about the exact mechanism of uptake of such delivery systems
is expected in the near future. Furthermore, it has been shown that even minor changes of the
physical state of a CPP (e.g., exchange of certain amino acids) can alter translocation properties
significantly. This particularly holds true for the attachment of large cargo molecules
[Veldhoen et al., 2008]. Thus, it might not be possible to generalize results obtained with a CPP,
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and it might be necessary to characterize each carrier/cargo complex individually. If CPPs are
proposed to be used for therapeutic purposes in the future, it is essential to focus on the
attachment of functional cargos and analyze their biological effects inside the cell. Data from
our lab clearly show that uptake and biological activity of a functional cargo is everything but
the same. Therefore, a quantitative comparison of cargo taken up and functionally active cargo
is an essential requirement in order to improve therapeutic efficacy. Indeed, only looking for
efficient internalization is not sufficient [Veldhoen et al., 2008].
The successful clinical application of nucleic acid-based therapeutic strategies has been limited
by the poor delivery efficiency achieved by existing vectors. The development of alternative
delivery systems for improved biological activity is, therefore, obligatory. Since two decades
ago that the Tat protein, and derived peptides, can translocate across biological membranes,
cell-penetrating peptides have been considered one of the most promising tools to improve
non-invasive cellular delivery of therapeutic molecules. Despite extensive research on the use
of CPPs for this purpose, the exact mechanisms underlying their cellular uptake and that of
peptide conjugates remain controversial [Trabulo et al., 2010].
There are many examples of CPP-mediated delivery of plasmid DNA into cultured cells and
also in vivo involving the use of a non-covalent approach [Bolhassani, 2011]. While some
approaches involve single component peptide vectors, the major focus has been on the
association of CPPs with other non-viral gene delivery methods, such as liposomes, polye‐
thyleneimine (PEI) or nanoparticles. In 1999, Morris and coworkers demonstrated that MPG
could be used as a powerful tool for the delivery of nucleic acids. It was shown that MPG is
not cytotoxic, insensitive to serum and able to efficiently deliver plasmid DNA into several
different cell lines [Morris et al., 1999]. Further studies demonstrated that cell entry of the MPG/
DNA particles is independent of the endosomal pathway and that the NLS of MPG is involved
in both electrostatic interactions with DNA and nuclear targeting. Furthermore, it was shown
that a mutation affecting the NLS of MPG prevents nuclear delivery of DNA. In an alternative
study, Rittner et al. described the novel basic amphiphilic peptides, ppTG1 and ppTG20 (20
amino acids), and evaluated their efficiencies in vitro and in vivo as single-component gene
transfer vectors. It was demonstrated that both the ppTG1 and ppTG20 peptides are able to
bind nucleic acids and destabilize membranes, in a liposome leakage assay. Complexes of
plasmid DNA with ppTG1 originated high levels of gene expression in cell culture experiments
and, most importantly, complexes of plasmid DNA with ppTG1 or ppTG20 led to significant
gene expression in vivo [Rittner et al., 2002]. Peptide modification has also been explored as a
means to enhance gene delivery. In particular, stearic acid modification of different membrane-
permeable arginine-rich peptides, such as HIV-1 Tat (48-60), HIV-1 Rev (34-50), flock house
virus (FHV) coat (35-49), (RxR)4 and oligoarginines of 4-16 residues was shown to substantially
increase their transfection efficiency. The mechanisms by which stearic acid modification
improves plasmid DNA delivery by CPPs have been shown to involve increased efficiency of
endosomal escape or enhanced cellular association, as well as higher nuclear delivery. The
extensively studied Tat peptide has also been exploited for plasmid DNA delivery by different
research groups, with paradoxical results [Trabulo et al., 2010, Bolhassani, 2011]. A study by
Ignatovich et al., demonstrated that Tat peptide is able to form complexes with plasmid DNA,
Novel Gene Therapy Approaches240
which could be used for gene delivery into mammalian cells. Despite reasonably high
transfection efficiency in vitro, low gene expression levels were detected in the liver of mice
injected intravenously with DNA-Tat complexes, a fact that was attributed to inactivation of
the complexes in the bloodstream due to interactions with serum albumin. Interestingly, an
endocytosis-dependent mechanism was proposed for the uptake of the DNA-Tat complexes,
similar to what was proposed for internalization of complexes of plasmid DNA with other
polycationic carriers. A different study, by Tung et al., compared the efficiency of a series of
Tat peptides, containing 1–8 Tat moieties. Although, all compounds complexed with plasmid
DNA, it was demonstrated that at least eight Tat peptide moieties are required in order to
achieve efficient gene delivery. Sandgren et al. also studied the cellular uptake of complexes
of plasmid DNA and the HIV-Tat derived peptide. According to this study, the Tat peptide
stimulated cellular uptake of DNA in a time-, concentration- and temperature-dependent
manner, while accumulating in large, acidic, cytoplasmic vesicles, followed by transfer of the
cargo into the nuclear compartment and subsequent disappearance from the endolysosomal
vesicles. Aiming at increasing the efficiency of the Tat peptide to deliver plasmid DNA, Lo et
al. made several modifications to the Tat peptide, through the use of histidine and cysteine
residues to enhance endosomal escape and complex stability [Trabulo et al., 2010]. Up to 7,000-
fold improvement in gene transfection efficiency was observed for the Tat peptide covalently
fused with 10 histidine residues (Tat-10H) over the original Tat peptide, and incorporation of
two cysteine residues into this peptide resulted in an even higher efficacy (C-5H-Tat-5H-C).
The association of CPPs with other non-viral delivery vectors has also been extensively
investigated, aiming at exploring the possibility to combine efficient delivery, packaging and
targeting moieties within the same system [Trabulo et al., 2010].
A combination of a peptide nucleic acids (PNA) with the SV40 core NLS, performed by
Branden et al., originated a bifunctional peptide that improved the efficacy of plasmid
transfection up to 8-fold when associated with the transfection agent polyethyleneimine (PEI)
[Branden et al., 1999]. Several other studies also combined PEI with CPPs. Kleemann et al.
covalently coupled the Tat peptide to 25 kDa PEI through a heterobi-functional PEG spacer
resulting in a Tat-PEG-PEI conjugate. Improved DNA reporter gene complexation and
protection were observed for small (approximately 90 nm) polyplexes as well as low toxicity
and significantly enhanced transfection efficiency in vivo [Kleemann et al., 2005]. Rudolph et
al. demonstrated that oligomers of the Tat peptide were able to condense plasmid DNA to
nanosized particles and protect DNA from nuclease degradation [Rudolph et al., 2003]. Most
importantly, when DNA was pre-condensed with Tat peptides and PEI, Superfect or Lipo‐
fectAMINE were added to the mixture, transfection efficiency was enhanced up to 390-fold
compared with the standard vectors. Similar studies by Kilk et al., demonstrated that the poor
transfection abilities exhibited by TP10 was significantly enhanced in the presence of PEI,
increasing several fold compared to PEI alone, particularly at low PEI concentrations, therefore
allowing the use of reduced PEI concentration [Kilk et al., 2005]. Using fluorescently labeled
liposomes and cargos, Torchilin et al. demonstrated that large drug carriers, such as 200 nm
liposomes, could be delivered into cells by attaching Tat peptide to the liposome surface. Next,
the same group described the formation of non-covalent complexes of Tat, liposomes and DNA
that were able to efficiently transfect cells both in vitro and in vivo, while being less toxic than
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other commonly used transfection reagents. The internalization of this system was claimed to
depend on a direct cytoplasmic delivery imparted by the Tat peptide [Torchilin et al., 2001].
A study by Hyndman et al. showed that mixing the Tat with liposomes containing DOTAP or
Lipofectin and DNA, resulted in complexes that significantly enhance transfection in vitro with
a marked reduction in the amount of liposomes required, despite the lack of any covalent
linkage of the peptide to liposomes. In this study, the use of endosomolytic agents and results
from experiments performed at low temperature suggested that the endocytotic pathway was
involved in the internalization of the complexes. Another report demonstrated that the
increase in gene transfer of Tat-modified lipoplexes is dependent on the amount of cationic
lipid in the lipoplexes and on the way, Tat was coupled to the lipoplexes. Moreover, it was
shown that the cellular uptake of both Tat-modified and un-modified lipoplexes was very fast
and, in contrast to previous publications, temperature-dependent [Hyndman et al., 2004]. A
concept called “Programmed Packaging” was proposed by Kogure et al., who developed a
multi-functional envelope-type nano device (MEND), consisting of a condensed DNA core
and a surrounding lipid envelope. This packaging method involves three steps: (1) DNA
condensation with a polycation, (2) lipid film hydration for the electrostatic binding of the
condensed DNA and (3) sonication to package the condensed DNA with lipids. MEND, having
octa-arginine on the envelope for enhancing cellular uptake, showed a 1000-fold higher
transfection activity than a DNA/poly-L-lysine/lipid complex prepared in similar conditions
[Kogure et al., 2004]. Another study, by Khalil et al., also described the high-efficiency delivery
of nucleic acids to eukaryotic cells using MEND particles containing polycation-condensed
nucleic acids encapsulated in an R8-DOPE lipid envelope. MEND particles were shown to be
non-cytotoxic and achieved transfection efficiencies as high as adenovirus [Khalil et al., 2010].
In this case, the high efficiency of MEND particles was ascribed, at least in part, to R8 which
was claimed to promote cellular uptake by macropinocytosis, improving intracellular traf‐
ficking towards more efficient gene expression. Along the same lines, work of the same
research group demonstrated that gene expression of condensed plasmid DNA encapsulated
in R8-modified nanoparticles was more than one order of magnitude higher than that of K8-
modified nanoparticles, and two orders of magnitude higher than gene expression using
unmodified nanoparticles. Differences in gene expression achieved with R8- and K8-modified
liposomes could not be attributed to differences in cellular uptake, since both kinds of
complexes were taken up primarily via macropinocytosis at comparable efficiencies. More‐
over, it was described that modification of nanoparticles with a high density of R8 allows their
escape from endocytotic vesicles via membrane fusion at both acidic and neutral pH, and that
the guanidinium groups of arginine residues, and not only their positive charge, are important
for efficient endosomal escape [Trabulo et al., 2010]. Recently, MacKay et al. described gene
transfer using PEGylated bio-responsive nano-lipid particles (NLPs) containing plasmid DNA.
In this study, the Tat peptide was attached either directly to a phospholipid (Tatp-lipid) or via
a 2 kDa PEG (Tatp-PEG-lipid); incorporation of 0.3 mol% Tatp-PEG into pH-sensitive NLPs
improved transfection 100,000-fold compared to NLPs. Although, Tatp-PEG-lipid could
dramatically increase gene expression in vitro, when tested in brain and in implanted tumors,
a restriction of NLP distribution to the vicinity of the infusion catheter reduced the absolute
level of gene transfer [MacKay et al., 2008].
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Over the last years, a research group focused on the S413-PV cell-penetrating peptide gener‐
ated from the combination of 13-amino acid cell penetrating sequence derived from the
Dermaseptin S4 peptide with the SV40 large T antigen nuclear localization signal [Trabulo et
al., 2010]. In these studies, complexes obtained through electrostatic association of the S413-
PV cell penetrating peptide with plasmid DNA are able to very efficiently mediate transfection,
particularly at high peptide/DNA charge ratios (5/1 and higher). Importantly, complexes
prepared with the S413-PV or reverse NLS peptides mediate transfection at significantly higher
efficiencies than those containing the scrambled version of the peptide, demonstrating the
importance of the cell-penetrating sequence derived from the Dermaseptin S4 peptide (amino
acids 1-13) to the transfection process. Additionally, we demonstrated that ternary complexes,
resulting from association of cationic liposomes to peptide/DNA complexes, are significantly
more efficient in mediating transfection than the corresponding peptide/DNA or cationic
liposome/DNA complexes [Trabulo et al., 2010]. In agreement with what has been described
for oligonucleotides, CPPs seem to be very efficient to mediate the uptake of plasmid DNA,
as well as lipoplexes and polyplexes containing DNA, surpassing the cell membrane barrier.
However, the challenge of overcoming the entrapment of complexes inside endosomes has
not been solved as easily as initially predicted, even taking advantage of the capacity of direct
translocation to the cytoplasm of some CPPs. Nevertheless, several of the studies described
above present promising strategies to overcome this limitation, such as chemical modification
of the peptide backbone or coupling of CPPs to other classes of delivery vectors. Overall,
accumulated evidence suggests that CPPs used in combination with other delivery systems
are more likely to be effective for gene therapy purposes than CPPs alone [Trabulo et al., 2010].
12. Bioactive peptides
As antibiotic resistance increases worldwide, there is an increasing pressure to develop novel
classes of antimicrobial compounds to fight infectious disease. Peptide therapeutic represents
a novel class of therapeutic agents. Some of them, such as cationic antimicrobial peptides
(CAMPs) and peptidoglycan recognition proteins (PGRPs), have been identified from studies
of innate immune effector mechanisms, while others are completely novel compounds
generated in biological systems. Currently, only selected cationic antimicrobial peptides have
been licensed, and for topical applications. However, research using new approaches to
identify novel antimicrobial peptide therapeutics, and new approaches to delivery and
improving stability, will result in an increased range of peptide therapeutics available in the
clinic for broader applications. A potentially rich source of peptide therapeutics that is being
investigated by researchers is the innate immune response, the effectors of which are produced
by eukaryotes to defend themselves against microbial attack [Oyston et al., 2009].
Human cancer is one of the most important causes of death in the western countries. In
advanced stages of the disease, the therapeutic opportunities are still limited due to the
difficulty to target specifically only cancer cells sparing healthy ones. Cancer cells have on their
surface antigens that are expressed at higher levels than their normal counterparts. Often these
antigens (also called tumor-associated antigens) have receptor activity and bind to specific
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proteins or peptides. The latter can be used for the specific delivery of anticancer drugs to
cancer cells through retargeting strategies and/or for the direct modulation of cancer cell
proliferation and survival interacting with cell-surface-specific receptors. These bioactive
peptides can be raised against either tumor cells themselves or to the tumor microenvironment
cell components (tumor vessels, tumor-associated macrophages, and fibroblasts) [Fields et al.,
2009]. However, the feasibility of pharmacological application of peptides depends on
absorption and bioavailability in intact forms in target tissues.
Moreover, their correct bio-distribution is sometimes hindered by biopharmaceutical obsta‐
cles, that is, protection by circulating protease-mediated degradation or specific accumula‐
tion in tumor tissues. Chemical modification of peptide backbone can increase the stability
of peptides in biological fluids. Moreover, the use of delivery systems, and in particular the
use of nanotechnologies, not only protects peptides from enzymatic degradation but also
improves the delivery of the bioactive peptide in the target tissue. Moreover, peptide conju‐
gation on the surface of nano-vectors can be useful for selective delivery of conventional
chemotherapeutic agents in tumor tissues. The requirements for an effective and safe der‐
matological therapeutic or active ingredient are included as following:
1. The molecule exhibits a proven specific beneficial bioactivity that would lead to a rational
demonstrable effect.
2. The bioactivity does not have a negative consequence either theoretically or experimen‐
tally due to its mechanism of action.
3. The molecule does not exhibit toxicity such as cytotoxicity, inflammation, immunogenic‐
ity, or mutagenicity.
4. The molecule is capable of reaching its desired target intact and in its active form.
5. The molecule can be formulated in such a way as to be stable, compatible with other
components, and be delivered effectively to the skin [Fields et al., 2009].
Collectively, these are not easily achieved criteria. For a new technology paradigm to
emerge, these criteria not only have to be met but be applicable across the wide range of
product-acceptable bioactivities. Peptides have significant advantages over many other tech‐
nologies in addressing these criteria primarily based upon their chemistry. Peptides consist
of chains of amino acids which can be modified in many ways to increase receptor binding,
increase specificity, decrease toxicity, and increase skin penetration, stability, and solubility.
In this way, the field of bioactive peptides for dermatological applications has changed sig‐
nificantly in recent years. From modest beginnings of a single peptide capable of stimulating
collagen, technological advances have created newer peptides capable of targeting most as‐
pects of dermal health. These advances include neutralizing toxins, stimulating fibroblast
scaffolding, reducing inflammation and other desirable effects [Fields et al., 2009].
13. Challenges in gene delivery for DNA vaccines
The goal of DNA vaccination is transfection of an antigen presenting cells (APC) or a bystander
cell to produce antigens in an immuno-stimulatory setting. The field of genetic vaccines has
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so far been limited by a lack of safe and effective gene delivery systems [Nguyen et al., 2008].
We attempted to mention some barriers and solutions (e.g., viral/non-viral methods) for DNA
vaccines individually.
13.1. Viral and non-viral methods for gene delivery
The main recombinant viral vectors used for gene delivery are adenovirus, adeno-associated virus
(AAVs), retrovirus and lentivirus. The advantages of adenovirus are infection of a wide range
of human cell types, ability to infect non-dividing cells and lower risk of insertional mutagen‐
esis. However, adenovirus expression is short lived and adenoviruses can cause a severe, even
lethal, inflammatory response due to prior immune exposure. AAV, which depends on
adenovirus or another virus for replication, has also been used for gene delivery with the
advantages of predictable chromosomal insertion and no known pathological consequence of
infection [Nguyen et al., 2008]. The main advantage of retroviruses, their ability to integrate into
the host genome for long-term expression, is also their main disadvantage as this integration
can cause mutagenesis and potentially cancer. Retroviruses are also further limited by their
inability to infect non-dividing cells. Lentiviruses, which can transfect a broad spectrum of cell
types, are the most efficient method to transfect DCs in vitro and in vivo. Yang et al. recently
reported very high levels of immune activation and therapeutic tumor rejection following
immunization with a lentiviral vector engineered to target DCs by the cell surface receptor
DC-SIGN [Yang et al., 2008]. In particular, Merck & Co. has advanced the use of viral DNA
vaccines for HIV vaccination. While there have been some successes in using viral gene therapy
and many clinical trials are currently ongoing there are currently no approved protocols.
Problems with viral delivery systems include immunologic priming to the vector itself,
oncogenicity due to insertional mutagenesis, difficult manufacturing and limited DNA cargo
capacity [Nguyen et al., 2008]. Clinical trials have highlighted some of these safety risks as
viral gene delivery has resulted in both cancer and deaths. Recently, Merck & Co. stopped its
Phase III HIV adenovirus vaccine prompting renewed questions about the utility of viral
vectors. The safety challenges and limitations of viral vectors have resulted in increased
interest in non-viral approaches to gene delivery using non-viral materials. In general, the non-
viral methods of DNA vaccination utilized in clinical trials, recently reviewed by Lu et al., rely
on physical methods. Injection of naked DNA plasmids has found limited success in humans
particularly when injected intramuscularly, even though in smaller animal models naked DNA
vaccination produces robust humoral and cell-mediated responses [Lu et al., 2008]. However,
the rapid degradation/clearance [half-life of under 5 min if injected intravenously (IV)] of
unprotected nucleic acids, poor induction of humoral immune responses in DNA vaccination
in larger animals and requirement for large doses has hindered progress into clinical trials.
Clinically, relevant physical methods that have been employed include electroporation,
ballistics (gene gun), ultrasound and magnetofection. Encapsulation or complexation of DNA
with a biomaterial can significantly enhance DNA stability, cellular uptake of DNA and final
protein expression. Materials shown to possess potential for the delivery of genes include
inorganic nanoparticles and surfaces that bind to or encapsulate DNA [Lu et al., 2008; Nguyen
et al., 2008]. Cationic biomolecules including lipids, polysaccharides, polymers, and dendrim‐
ers can also electrostatically complex anionic DNA to facilitate transfection. Unless specifically
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designed to do so, DNA delivered non-virally has low potential for genomic integration
[Nguyen et al., 2008]. Non-viral delivery systems for gene therapy are generally cheaper to
manufacture, easily scalable from laboratory to GMP-scale production and are typically more
robust for long-term storage compared to their viral counterparts. Despite achieving greater
efficacy than naked DNA administration (IM, IV or otherwise), physical methods for gene
delivery are often limited due to local tissue damage and insufficient gene expression. Research
into non-viral gene delivery has been ongoing since the 1970s, and as understanding of the
mechanisms of gene delivery has grown, the design of synthetic biomaterials has become more
advanced. However, while there have been advances, non-viral methods of gene delivery
generally still have lower efficacy than viruses [Nguyen et al., 2008].
13.2. Barriers to gene delivery for DNA vaccines
There are many potential blocks that must be overcome for successful DNA delivery, a process
broadly defined as transfection. Plasmid DNA must first be packaged into particles. Require‐
ments for gene delivery include protection of plasmid DNA from degradation, localization to
the tissue and cell types of interest avoiding off-target distribution, minimal inactivation by in‐
teraction with serum proteins, low clearance from the blood or interstitial space and efficient
transport through the extracellular matrix to the surface of target cells. Next, the DNA-contain‐
ing particles must associate with cells and become internalized into them by cellular uptake
processes [Nguyen et al., 2008]. Following uptake, DNA-containing particles must escape the
endosomal/ phagosomal compartment into the cytoplasm and release their DNA cargo. DNA
must finally translocate into the nucleus to be transcribed into mRNA and subsequently trans‐
lated into protein antigen. Viruses have evolved to accomplish these steps and provide a frame‐
work for the design of synthetic delivery particles. Despite efficient uptake of particles of a
variety of sizes, in vitro and in vivo transfection of DCs is still notoriously difficult to achieve.
APCs are specialized not only for uptake of antigen but also rapid and efficient antigen process‐
ing. As a key role of APCs is to internalize and process pathogens for immune activation, APCs
may have greater protection against foreign (viral) DNA entry into the nucleus, which may be a
barrier to DNA vaccination. Whereas in vitro investigation of transfection efficiency in cell cul‐
ture can be used to identify promising materials for transfection, there exist multiple extracellu‐
lar barriers to effective DNA vaccination in vivo. DCs reside in the blood, in the skin (Langerhans
cells), other mucosal barriers, and in lymph nodes [Nguyen et al., 2008]. macrophages (MPs) al‐
so exist in lymph nodes, as circulating precursors in the blood (monocytes) that differentiate as
they enter inflamed tissue cites, and as specialized MPs lining the spleen and liver (Kupfer cells)
forming the phagocytic part of the reticuloendothelial system (RES). Access to these APCs is
therefore determined not only by route of injection, but also by ability of a particle to drain into
lymphatic systems or activate inflammatory signals to recruit APCs. For example, Reddy et al.
have illustrated size-based targeting of lymph-node resident DCs by accessing lymphatic ves‐
sels with 25 nm particles; lymphatic drainage and DC uptake was significantly reduced with
100 nm particles [Reddy et al., 2007]. Many cationic delivery materials, both polymeric and lip‐
id, form vector-nucleic acid particle (VNP) complexes by electrostatic interactions with the neg‐
ative charges on the phosphate groups of the DNA backbone. A net positive surface charge can
facilitate transfection by interacting with the negatively charged glycoproteins at the cell mem‐
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brane. However, electrostatic interactions can also rapidly lead to aggregation of these VNPs
with serum proteins; as VNP-protein aggregate size increases they can be eliminated from cir‐
culation by the phagocytic MPs of the RES, deposit non-specifically in microvascular beds or
crash out of solution, which may cause acute toxicity [Nguyen et al., 2008]. In addition to con‐
taining high concentrations of negatively charged proteins, plasma also has a significant ionic
strength. Interactions between serum proteins, blood and interstitial fluid solutes and polyca‐
tionic carrier materials can lead to competitive binding, destabilization of the VNP and subse‐
quent premature release of the nucleic acid payload. Interaction with complement proteins, C3
and C4 in particular, can activate the innate immune responses resulting in acute inflammation
and lead to severe acute toxicity or death. Mucosal surfaces and serum also contain DNase and
RNase enzymes that specifically degrade nucleic acids. Condensed VNPs prevent the degrada‐
tion of the nucleic acid payload by steric inhibition of these DNases/RNases. The addition of
PEG and other hydrophilic polymers can be used to prevent aggregation with serum proteins
and subsequent rapid clearance [Nguyen et al., 2008]. This simple functionality can sharply in‐
crease the serum half-life of a particle and prevent acute toxic events due to non-specific interac‐
tions, but also results in lower transfection efficiency and reduced cellular targeting. Toxicity at
the cellular level and/or due to interactions with the immune system, liver, kidneys, or other
complex organ systems can be a concern with non-viral gene delivery. For example, PEI has
been shown to be an effective transfection agent but has also been reported to be toxic in animal
models. Polycations such as PEI and cationic lipids such as 1, 2-dioleoyl-3-trimethylammoni‐
um-propane (DOTAP) also tend to activate complement and the reticuloendothelial system
(RES) aggregate with serum proteins, and can aggregate with red blood cells as well. Some tox‐
icity issues both in vitro and in vivo can be addressed by chemical modification of PEI [Nguyen et
al., 2008]. For increased safety, biodegradable gene delivery systems have also been developed,
including degradable cross-linked PEI [Kim et al., 2005], poly (ortho-esters) (POE) [Heller et al.,
2000] and poly (b-amino esters) (PBAE) [Anderson et al., 2003].
13.3. Particle uptake by APCs and targeting gene delivery for DNA vaccines
Particle uptake by phagocytosis (particles > 500 nm), macropinocytosis, and receptor-mediated
endocytosis are particularly important routes of entry into APCs. Delivery systems can be
designed to exploit these ways. Cell-specific targeting can significantly enhance transfection
efficiency and the desired therapeutic outcome. The direct conjugation of targeting moieties
such as receptor ligands, peptides, sugars, aptamers and antibodies can increase cell and tissue
specificity and transfection efficiency. Additionally, targeting can be based upon size-specific
signals to avoid off-target affects. A variety of strategies exist for targeting APCs. First, APCs
express Fc-receptors, which bind to the constant region of antibodies to facilitate uptake of
antibody-coated foreign bodies. APCs also express complement receptors that help clear
complement-opsonized particles [Nguyen et al., 2008]. Lectin-binding receptors, such as the
mannose receptor and scavenger receptors that recognize apoptotic bodies, certain bacterial
components and other non-self motifs are PRRs commonly found on APCs that can enhance
particle uptake and may trigger innate immune activation. Second, unlike most other cell
types, immature DCs constitutively sample their extracellular fluid environment non-
specifically through macropinocytosis to maintain immune surveillance and vigilance for
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foreign particles, as well as to present endogenous proteins for maintenance of self-tolerance.
This constant sampling may explain DC-targeting by particle size. Particle size may also
influence the specific route of entry, as reviewed recently by Xiang et al. Particle surface
characteristics also play a role in uptake, as cationic particles more readily associate with the
negatively charged glycoproteins on the cell surface and promote non-specific uptake, and
other surface characteristics can activate opsonization [Xiang et al., 2006]. Champion et al. have
clarified the role of particle shape in influencing phagocytosis by MPs, as well as provided
simple methods for creating materials with complex shapes and sizes to take advantage of
particle physical properties. While spherical micro- and nano-particles are efficiently phago‐
cytosed by lung alveolar MPs, phagocytosis can be inhibited by contact with odd geometries
due to an inability to form the necessary actin structures. In general, size plays a more
significant role with particle association with the cell surface than with internalization. These
studies suggest a role for particle surface nano and micro-structure in the design of APC-
targeted DNA vaccine delivery systems [Champion et al., 2007].
13.4. Biomaterials for DNA delivery: Non-polymeric biomaterials for gene delivery
Many materials have been developed for gene delivery. Early chemical methods of increasing
the efficacy of gene delivery focused on co-precipitation of the DNA with salts such as calcium
phosphate. More recently, inorganic materials have also been combined with polymers to form
hybrid gene delivery nanoparticles. For example, textured surfaces and silica nano-particles
have been shown to be effective for gene transfer in vitro and organically modified silica nano-
particles have been shown to deliver genes in vivo. Gold nano-particles have also been com‐
bined with PEI for hybrid gene delivery systems. Cationic lipids have been the non-viral gene
delivery vectors of choice for clinical application since Felgner first introduced their use in 1987.
The cationic lipid molecule consists of a hydrophilic positively charged head group, a linker
that may impart some functionality such as pH sensitivity and a hydrophobic long chain tail
[Felgner et al., 1987]. A prototypical cationic lipid is DOTAP; it is the most widely used lipid for
gene delivery. For in vivo delivery, nucleic acids are usually encapsulated into liposomes: vesi‐
cles with lipid bilayer membranes that exist as large uni-lamellar vesicles (LUVs) or multi-la‐
mellar vesicles (MLVs). Liposomes generally consist of a single cationic lipid or a mixture of
cationic lipids that facilitate nucleic acid binding and transfection, cholesterol or diolelphopha‐
tidylethanolamine (DOPE) to impart some rigidity or stability to the complex, and PEG to shield
particles from aggregation, serum components, or other non-specific interactions. Lipids have
been used extensively in gene therapy and are the main non-viral delivery vectors used in clini‐
cal trials. Unfortunately, some lipoplexes are toxic, interact nonspecifically with serum proteins
and cells, aggregate quickly, activate the complement system, or have low in vivo efficacy. One
promising approach that may address these problems is to increase the chemical diversity of
lipid-like materials through combinatorial synthesis approaches [Nguyen et al., 2008].
14. Conclusion
Gene therapy possesses great potential for combating a variety of diseases. Initial results are
promising and some technologies have advanced to clinical trials. Yet challenges remain, and
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despite decades of study, safe and efficient gene delivery remains a major blockage in human
medicine. The current progresses of gene therapy are further focused on synthesized nano-
particle technologies such as polymers (PLGA, chitosan and PEI), lipids and peptides. It is
necessary to understand the effects of particle size, surface characteristics and material
interactions. Research on cell penetrating peptides (CPPs) as gene/ drug delivery systems has
clarified their capacity to promote the efficient internalization of therapeutic biomolecules.
Despite differences in size, charge and/or structure between different bioactive molecules, it
is clear that CPP-based systems appear to be very versatile and efficient delivery is achievable
following proper adjustment of the carrier to the transported biomolecule. Because the
development of drug, oligonucleotide or gene delivery systems is aimed at a clinical applica‐
tion, the design of these novel delivery vectors should consider other important issues
including safety, bio-distribution, ease of manufacturing, scale-up, reproducibility and
analytical and physical characterization. The advance of CPP technology depends on the
development of strategies that facilitate endosomal escape and that confer cell specificity to
these systems. A careful investigation of the mechanisms of internalization of CPP-cargo
complexes or conjugates will greatly help the improvement of this powerful technology.
However, a viable non-viral gene vector for systemic delivery depends on its capacity to bypass
a series of physiological barriers and its efficiency in carrying nucleic acids to a targeted site
within a cell. The concept of a multifunctional delivery system helps to solve the problems
associated with various barriers. The availability of delivery devices directed towards each
individual barrier, provides a basis for this direction, although the complexity in the devel‐
opment of multifunctional non-viral vectors is much more than a merely combination of
various devices into a single system. In order to achieve the optimal gene delivery, the
researchers have focused largely on the evolution of “intelligent” bio-responsive materials, as
well as on the advances in formulation technologies. In this process, a number of strategies
have emerged including the balances between gene packing and controlled release, and
optimal control between long-circulation and intracellular trafficking that promotes safer and
more efficient delivery of gene/drug in a systemic context.
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